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Autism spectrum disorders (ASD) are lifelong severe disabling conditions affecting 
around 1-2% of the global population (Elsabbagh et al., 2012; Baxter et al., 2015; Christensen 
et al., 2016). In the past decade, improvements in whole genome sequencing methods 
allowed the identification of increasing numbers of risk genes associated with ASD. Studies 
suggest that risk genes converge in several common molecular, metabolic, or circuit pathways 
(de la Torre-Ubieta et al., 2016). Despite these recent advances in the biological understanding 
of ASD, no efficient treatments have been found yet. Therefore, identifying the function of 
individual genes leading to converging alterations is a major challenge to define mechanism 
based stratification of the disorder. 
 
The goal of my study was to explore the functions of the Patched domain containing 
protein 1, a poorly understood risk gene strongly associated with ASD and intellectual 
disability (ID) (Noor et al., 2010; Chaudhry et al., 2015). PTCHD1 appears to be a highly 
penetrant mutation with around 45% of affected individuals having ASD and/or ID (Chaudhry 
et al., 2015). It is estimated that mutations in the PTCHD1 locus occur in approximately 1% of 
individuals with ASD (Noor et al., 2010). Thus, compared to other genetic risk factors, PTCHD1 
mutation appear to be a common and very penetrant alteration associated with ASD. To date 
the Ptchd1 protein has remained largely uncharacterized, therefore, there is a lack of insights 
into how PTCHD1 mutations may lead to ASD related phenotypes. The gene encodes for a 
transmembrane protein that shares a sterol-sensing domain with the Sonic hedgehog (Shh) 
receptor Patched (Ptch1) and Niemann-Pick disease, type C1 (NPC1), a cholesterol transport 
protein. Based on this sequence similarity and transcriptional reporter assays in cell lines, it 
has been hypothesized that Ptchd1 may contribute to Shh signaling (Noor et al., 2010).  
 
Here I report, using a mouse knock-out model and biochemical assays, that Ptchd1 
removal has no effect on Shh dependent neuronal proliferation, in addition, Shh does not 
show any binding to Ptchd1 in vitro. In an unbiased search for Ptchd1 interacting proteins, I 
recovered three components of the retromer complex involved in regulating dendritic protein 
trafficking between endosomal compartments and the plasma membrane (Choy et al., 2014): 
Sorting-nexin 27, VPS26B and VPS35. In addition, several postsynaptic density proteins were 
recovered: Dlg1,2,3,4 Magi1,3, Lin7. Considering a potential synaptic role for Ptchd1, we 
performed electrophysiological recordings on Ptchd1 knock-out animals in granule cells of the 
dentate gyrus, a cell population where Ptchd1 is highly enriched. We observed that loss of 
Ptchd1 results in a disruption of excitatory/inhibitory balance in the mouse hippocampus. 
Finally, Ptchd1 KO animals also showed deficits in hippocampus-related behavioral tasks.  
 
Thereby, my study provides evidence that Ptchd1 loss-of-function experiments do not 
support a role in sonic-hedgehog-dependent signaling but reveal a profound disruption of 
synaptic transmission in the mouse dentate gyrus and support an association of Ptchd1 with 
dendritic trafficking complexes and synaptic scaffolding proteins. 
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1.1 General introduction 
 
The development of the brain is orchestrated by complex genetic programs defining 
distinct and specific cellular functions. The resulting cellular and molecular diversity aims to 
build an efficient neuronal network but the correct functioning of the brain is a fragile balance 
where a single genetic mutation can induce severe neurodevelopmental disorders. Thereby, 
understanding how genetic mutations lead to complex neurodevelopmental disorders is a 
major challenge for neurobiologists. Mutations can affect specific brain functions such as 
cognitive, emotional, learning, social or motor processing but they often result in a 
combination of phenotypic alterations. In the past decades, several neurodevelopmental 
conditions have been linked with rare genetic mutations such as Fragile X, Tuberous sclerosis 
or Rett syndrome.  However, in most cases developmental brain alterations arise from a 
combination of multi-genic and environmental factors often leading to complex and severe 
conditions such as autism spectrum disorders (ASD), schizophrenia or bipolar disorders. ASD 
appears to be the most prevalent of neurodevelopmental disorders with around 1-2% of the 
global population affected (Elsabbagh et al., 2012; Baxter et al., 2015; Christensen et al., 
2016). In the past decade, there has been a converging line of research, especially twin studies 
and sequencing studies, suggesting that ASD has a strong genetic component (Folstein and 
Rutter, 1977a; Ronald and Hoekstra, 2011; Geschwind and State, 2015) . With the 
improvement of genome wide sequencing methods, more than a hundred of risk genes have 
been identified and the list is constantly increasing (Geschwind and State, 2015). A great 
number of risk genes are suggested to converge in common molecular, cellular or metabolic 
pathways (de la Torre-Ubieta et al., 2016). However the link between gene mutation and 
altered phenotype is, in most cases not elucidated. In addition, with new risk genes constantly 
added to the list, a great number of them stay unstudied. 
 
 Thus, the pathophysiology of ASD remains poorly understood with no clear 
therapeutic targets identified. Thereby disentangling the genetics of ASD is essential to 
establish a mechanism-based stratification of different ASD forms and thereby provide 
targeted molecular therapies. 
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1.2 Autism spectrum disorders: a single condition? 
 
1.2.1 A historical perspective 
 
In the late 1800s, a period when interest towards mental illness was starting to 
emerge, the term “autism”, from the Greek word “autos” meaning “self”, was first reported 
by Dr. John Langdon describing the “autistic thinking” of patients having Down’s syndrome. 
At the time, the term “autistic” was referring to a person who is “cut off the world of people”. 
Later in the early 1900s Eugen Bleuler and his student Eugène Minkowski, used the term 
autism to describe symptoms of what they called “dementia praecox” (early psychosis) later 
named childhood schizophrenia. In both cases, the word autism did not yet refer to the 
current definition, but rather a simplistic description of mental retardation. 
 
In the 1940s that Leo Kanner (Johns Hopkins Hospital, United States) and Hans 
Asperger (University of Vienna, Austria) conducted in parallel similar observations on children 
and characterized for the first time patients having difficulties to deal with social interaction 
and communication. Even though both practitioners described similar observation around the 
same period, Leo Kanner documented more carefully his observations and identified 
children’s difficulties to deal with non-social changes and was the first to use the concepts of 
“resistance to change” and “insistence on sameness”. In addition he also distinguished autism 
from mental retardation and described some of the affected children as “feeble minded”. Leo 
Kanner and Hans Asperger’s observations were close to the current definition of ASD, however 
it was not yet considered as a separate disorder and the confusion with mental retardation 
and “childhood schizophrenia” still remained.  
 
After the second world war many child psychiatrists were still diagnosing children 
presenting social deficits/repetitive behaviors with child schizophrenia, often interpreting its 
origin in psychoanalytic terms. An interpretation that gained a lot of attention at the time, 
was that the condition is a form a rejection of reality in response to an emotionally cold and 
distant mother (also known as the “refrigerator mother” theory). Parental education being a 
cause for autism was a popular theory in the 1960s, mainly because some psychiatrists 
reported that most of the affected children came from highly educated families; which led 
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practitioners to conclude that autism was specific to high-status families and deviant 
parenting could be a cause of autism. However, it was without considering the selection bias 
that well informed and educated families have more chance to find a psychiatrist and diagnose 
their child. Thus, several child psychiatrists later focused on the question and found no link 
between parental education and ASD (Rutter, 1979) . 
 
It is only in the early 1970s that the biological origin of ASD started to emerge with the 
establishment of precise clinical models and epidemiological studies. Pioneering studies led 
by Michael Rutter suggested that ASD and schizophrenia were genetically dissociated by 
showing that patients with ASD did not have increased rates of schizophrenia compared to 
the general population (Rutter, 1972). Similarly, Israel Kolvin’s established that ASD and 
schizophrenia had independent developmental trajectories and different ages of onset 
(Kolvin, 1971). From that point onwards, clinicians defined a more detailed diagnostic model, 
including the early onset (within 30 months of age) of social interaction deficits, behavioral 
rigidities, hyper/hyposensitivity to the environment and language deficit or absence of 
speech. 
 
In the late 1970s Susan Folstein and Michael Rutter conducted the first studies 
comparing twins with either one or both having autism. The studies concluded that there was 
a very high concordance rate for autism between twins and thereby highlighted for the first 
time the heritability of autism (Folstein and Rutter, 1977b).These converging studies strongly 
contributed to recognize “infantile autism” as a separate diagnosis in the third edition of 
Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980. 
 
In 1987, the term “infantile autism” was renamed to “autism disorder” with the aim to 
orient the diagnosis to a broader developmental approach (not only limited to young 
children). Thereby some major changes were made to the definition of the diagnosis in the 
revision of the DSM-III (DSM-III-R); sixteen criteria were established within three major groups 
of dysfunctions: (1) qualitative impairment in reciprocal social interaction, (Andersen and 
Koeppe) qualitative impairment in communication and (3) restricted interests. Eight criteria 
out of sixteen had to be met to diagnose autism disorder, with at least two from the social 
category and one each from the other two categories. This detailed diagnostic scheme gave 
Introduction 
 21 
more flexibility to clinicians for establishing an accurate diagnosis and focused more on the 
behavioral changes during development. However, the early onset of the disorder was often 
missed and gave a significant number of false positive cases, mainly patients with intellectual 
disability.  
 
 In the 1990s a series of field trial compared different version of diagnostic schemes 
including DSM-III, DSM-III-R and the World Health Organization’s International Statistical 
Classification of Diseases and Related Health Problems (ICD-10). In 1994, after multiple 
analysis comparing the diagnostic schemes, a new class of subthreshold condition of autism 
was added to the DSM-IV. In other words, patients meeting some but not full autism 
diagnostic criteria were categorized under the “pervasive developmental disorders” (PDD) 
category also referred as “atypical autism” in the ICD-10. This category included “childhood 
disintegrative disorder”, Rett syndrome (a genetic disorder including social impairment and 
severe motor dysfunctions) and Asperger syndrome (patients with social deficits but no 
impairment in communication and normal or higher than average cognitive functions).  
 
Finally in 2013, the fifth edition of the DSM adopted the term “autism spectrum 
disorder” with the aim to better define the different dimensions of the disorder not only for 
clinical but also for neurobiological purposes. The current definition merges impairment in 
social interaction and communication in one group, but kept restricted and repetitive 
behaviors as a second core feature. The term “spectrum” replaces the PDD terminology and 
aims to highlight the variety and complexity of comorbid disorders associated with the core 
symptoms.  
 
In sum, since the early 1800s there has been a considerable effort to shape the 
definition of ASD. First, it helped to recognize and define the disorder as a separate and 
complex condition, then guided clinicians to make an accurate diagnostic with the aim to 
provide adapted care to patients.  
 
1.2.2 Distinction between core and associated symptoms 
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To meet full ASD diagnosis according to the DSM-V, a person must show deficits in all 
features of the social interaction/communication category:  
 
1. Social-emotional reciprocity  
2. Non-verbal communication  
3. Understanding and maintaining relationships. 
 
In addition, the person must demonstrate deficits in two out four features in the 
restricted/repetitive behaviors cluster: 
 
1. Repetitive speech/behavior 
2. Insistence on sameness 
3. Restricted interests 
4. Sensory abnormalities. 
 
Deficits in social interaction/communication and restricted/repetitive behaviors 
currently define the two core symptoms of ASD, however the disorder is often accompanied 
by several comorbidities that shape a heterogeneous and complex spectrum. Associated 
symptoms are often reported to be more disabling on a daily bases than the core symptoms. 
As illustrated in Figure 1, comorbidities are very heterogeneous and can affect cognitive, 
behavioral as well as more autonomous functions such as the gastrointestinal tract and sleep 
rhythms. 
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Figure 1. Heterogeneity of ASD comorbidities. Adapted from Veenstra-VanderWeele and Blakely 
(2012). Core symptoms are described in blue circles. Comorbidities are shown in red circles. Associated 
symptoms can be behavioral such as hyperactivity, impulsivity, anxiety, aggression, depression; or/and 
cognitive: intellectual disability, language impairment; and/or medical: sleep, gastrointestinal, seizure 
disorders. 
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Within the ASD behavioral comorbidities, intellectual disability (ID) appears to be the 
most frequent, with approximately 1/3 of patient being affected (Chakrabarti and Fombonne, 
2005; Fombonne, 2009; Postorino et al., 2016). Diagnosis of ID involves several test such as 
intellectual functioning (IQ tests) and emotional/social maturity, however the evaluation 
methods can differ across countries which makes epidemiologic studies difficult to establish. 
In addition, self-injury and aggression are also commonly observed in individuals with ID. The 
debate remains on whether or not emotional/social interaction disorders can be a cause of 
ID; in other words when ASD is diagnosed with ID, the core symptoms of impaired social 
communication/ interaction could be a consequence of ID and not a core feature anymore. 
 
Anxiety disorders are also commonly diagnosed with ASD and often observed when 
the repetitive routine is changed and/or an unexpected or novel task has to be initiated. 
However it remain unclear whether or not the anxiety state causes the repetitive disorders or 
if the restricted/repetitive rigidity create the anxiety towards change/novelty or unexpected 
events. 
 
Within the medical comorbidities, epilepsy is often an early sign leading to the 
detection of ASD with around 20-30% of individuals affected (Francis et al., 2013; Viscidi et al., 
2013). It has been hypothesized that epilepsy could play a role in regressive ASD (individuals 
loosing acquired skills during preschool period including language, social skills, etc.). However, 
current studies do not support a strong correlation (Tuchman, 2006; Besag, 2018). 
 
Overall, the comorbid symptoms discussed above are more likely to occur in 
individuals with ASD compared to typically developing persons (Elsabbagh et al., 2012), and 
for most of the comorbidities it is still debated whether they are a cause or a consequence of 
the core symptoms. With the complexity and heterogeneity of core and associated symptoms 
each individual with ASD is a unique case and therefore needs careful diagnosis and adapted 
care. Over the past decade, considerable efforts have been made to create diagnostic tools to 
identify and dissociate core from associated symptoms. Standardized diagnosis tools are 
important to identify and treat comorbidities when medications or therapies are available. 
However standardization also has limitations, diagnosing one dysfunction (for example ID) 
may lead to miss the identification of more subtle dysfunctions (mental illness, 
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communication impairment, physical pain, etc.), called “diagnostic overshadowing”. Also, 
attributing a multitude of symptoms, often negatively seen by the society, to an individual 
with ASD can also be very stigmatizing and worsen the symptoms.  
 
Some comorbidities can be attenuated with medication (hyperactivity, anxiety, 
aggression, sleep) but are often accompanied by undesired side effects. Behavioral therapies 
can improve to various degrees some of the core symptoms but are inefficient in many cases. 
Overall, there is currently no adequate treatment targeting the core symptoms, mainly 
because the biological understanding of ASD just started to emerge. Since researchers started 
investigating the comorbidities on a biological level, it raised the question on whether 
different ASD symptoms arise from a single underlying etiology or whether different biological 
deficits cause converging ASD symptoms. Over the past decade, the improvement of research 
tools (brain imaging, cell imaging and molecular biology tools) provided elements of response 
with the identification of several biological alterations. 
 
1.2.3 Biological deficits 
 
Understanding the pathophysiology of ASD is an essential step toward the 
development of specific molecular therapies. Recent studies reported biological dysfunctions 
at various levels including anatomical, circuit, cellular and/or molecular levels (de la Torre-
Ubieta et al., 2016). This section highlight the principal biological alterations identified so far. 
 
 Anatomical alterations often include brain overgrowth during early child hood that 
either can persist over time or be followed by a growth normalization during development. 
Abnormal head circumference (macrocephaly or microcephaly) is also observed in 
approximately 20% of children with ASD (Fombonne et al., 1999). Not all brain regions are 
affected by an overgrowth pattern but the frontal lobes and anterior temporal regions, 
involved in processing language and social cognition (Amaral et al., 2008) appear to be the 
most affected (Courchesne et al., 2007).  
 
 Growth alterations also suggest underlying circuit deficits. Altered functional 
connectivity with disruptions in short and long-range connections is strongly associated with 
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ASD. Studies report either under or over-connectivity in both local and long-range connections 
(Courchesne and Pierce, 2005; Anderson et al., 2011; Keown et al., 2013). Several studies from 
human derived cells and mouse models, report alterations in excitatory (E) or inhibitory (I) 
circuits, which led to the hypothesis that an imbalance of excitation over inhibition (E/I ratio) 
contributes to ASD pathophysiology (Shcheglovitov et al., 2013; Nelson and Valakh, 2015; 
Patriarchi et al., 2016).  
  
 Connectivity can be also structurally altered in ASD, with disruptions in neuronal 
cytoarchitecture. Post-mortem brains of ASD patients and mouse models showed alterations 
in neuronal density, size and localization (Casanova et al., 2002; Casanova et al., 2006) 
 
 Excitatory and inhibitory neurotransmission is processed by synapses and 
malfunctioning synapses are thought to be strongly contributing to ASD (Kleijer et al., 2014; 
Ebrahimi-Fakhari and Sahin, 2015). Several genes encoding for synaptic proteins have been 
closely linked with ASD : Synaptic adhesion molecules (neurexins, neuroligins) (Jamain et al., 
2003; Vaags et al., 2012; De Rubeis et al., 2014), Synaptic scaffolding proteins (SHANKs, 
Gephyrins) (Durand et al., 2007; Berkel et al., 2010; Lionel et al., 2013) and post-synaptic 
receptors (GABA and NMDA) (De Rubeis et al., 2014; Krumm et al., 2015). Synaptic dysfunction 
in ASD also includes altered synaptogenesis (Garcia-Penas et al., 2012; Habela et al., 2016) 
and synaptic pruning deficits (Hutsler and Zhang, 2010; Tang et al., 2014). 
 
Deficits in neuronal translation are also associated with ASD. Two relevant examples 
directly linking disruption in protein synthesis and ASD syndromes are Tuberous sclerosis and 
Fragile-X syndromes, two monogenic form of ASD. Both syndromes are characterized by 
mutations in a gene encoding for key repressors of the neuronal translation machinery 
(respectively TSC1/TSC2 and FMRP proteins). Thereby, dysregulation of translational 
repression leads to major imbalances in protein production, which can result in several 
neuronal dysfunctions, including over-proliferation, cell death or synaptic dysfunction (Bassell 
and Warren, 2008; Ehninger and Silva, 2011). 
 
Finally, neuro-inflammation has also been recently linked to the pathophysiology of 
autism. Human post-mortem brain studies reported microglial activation and astrocytosis in 
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multiple brain regions, mainly dorsolateral prefrontal cortex and cerebellum (Vargas et al., 
2005; Morgan et al., 2010). Additionally, studies found several inflammatory biomarkers in 
the serum, plasma, and cerebrospinal fluid of children with ASD (Zimmerman et al., 2005).  
Neuro-inflammation in ASD is not yet well understood and causal genetic variants have not 
yet been clearly identified. Thereby the question remains on whether neuro-inflammation is 
a response to upstream neuronal alterations or rather an independent dysfunction. 
 
 As highlighted above, the pathophysiology of autism is very diverse and appears to be 
a “whole body” disorder rather than a single psychiatric condition. Even though converging 
biological mechanisms have been implicated, no unique biological dysfunction leading to ASD 
has been identified so far. Current findings support that distinct pathologies converge to a 
spectrum of cognitive and behavioral disorders defined as ASD. This heterogeneity in the 
pathophysiology of ASD also makes challenging the identification of predictive biomarkers for 
early detection. Eye tracking studies show promising results but there is still controversy on 
whether they constitutes a good predictive ASD biomarker (Pantelis and Kennedy, 2017). 
Despite the lack of accurate biomarkers, a number of predictive environmental and genetic 
risk factors have already been identified. 
 
1.2.4 Risk factors 
 
1.2.4.1 Environmental risk factors 
 
Environmental risk factors refer to all factors that are not determined by intrinsic 
biological mechanisms. Thereby, the term can be interpreted rather widely and englobe 
mother’s drug use, medication, infections, diet, exposure to environmental chemicals or even 
stress. The embryonic development seems particularly sensitive its surrounding environment 
but the post-natal period and even parental life style before conception are thought to 
influence brain development (Lyall et al., 2017). However, demonstrating a clear causal link 
between an environmental factor and a disorder is often very challenging. Ideally, it would 
require testing the effect of a single risk factor by keeping all the other parameters unchanged 
in a representative population sample. This laboratory experimental design is realistically not 
applicable for overlapping environmental factors acting at different time on individuals with 
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different ages, life-styles and genetic backgrounds. Most of the recently established 
environmental risk factors were identified with epidemiological or mouse model studies that 
provide mainly correlations between a risk factor and ASD. As manifestations develop very 
early after birth, the time window for environmental factor to contribute to the disorder 
postnatally is limited. Studies suggest that risk factors are mostly susceptible to act prenatally 
during embryonic development (Bilder et al., 2009; Buchmayer et al., 2009). The embryonic 
development is subject to different vulnerability windows but the first trimester of pregnancy 
appears to be the most sensitive period (Bilder et al., 2009; Buchmayer et al., 2009). The list 
of environmental triggers is constantly increasing but correlational links are often 
questionable due to the limited sample size of epidemiological studies and the lack of 
reproducibility. The following sections highlights only factors with the strongest associative 
evidence. 
 
Exposure to pharmacological agent during pregnancy is thought to be a major risk 
factor contributing to neurodevelopmental disorders. Valproic acid, an antiepileptic and 
mood stabilizer drug, when taken during pregnancy, is well documented to be one of the 
highest ASD risk factor (Hiilesmaa et al., 1980; Ornoy, 2009; Roullet et al., 2013; Choi et al., 
2016). Similarly, Thalidomide another teratogen (banned from sale since the 1960s) is also 
strongly associated with ASD (Stromland et al., 1994; Rodier, 2002). Misoprostol a 
prostaglandin analog (prescribed in the treatment of gastric ulcer) and Beta-2 adrenergic 
drugs (such as terbutaline used in the treatment of asthma) have also been reported to be 
associated with ASD (Bandim et al., 2003; Witter et al., 2009). 
 
 Some virus infection have also been reported to be a high risk factor for autism. 
Congenital rubella infection appears to be a major risk to develop ASD and, with only 
moderate evidence, congenital influenza seems to be linked with ASD as well  (Libbey et al., 
2005). Vaccination gained increasing attention in the early 2000s as being a potential ASD 
trigger. This resulted largely from a single study, later retracted for a number of scientific 
inconsistencies including uncontrolled design, small sample size (n=12), and speculative 
conclusions (Rao and Andrade, 2011). In addition, a number of concerned parents reported 
that their child developed ASD following vaccinations, without taking in consideration that 
first signs of ASD arise around the same period than child vaccinations and correlation does 
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not mean causality. Following these concerns a number of epidemiologic studies have been 
conducted and consistently showed no link between ASD and vaccines (Hurley et al., 2010; 
Maglione et al., 2014). 
 
Embryogenesis is particularly sensitive to the mother’s environment. Environmental 
chemicals (mercury, neurotoxicant, pesticides), drug use (cocaine, alcohol), diet (vitamin D 
deficiency), air pollution and stress exposure during pregnancy are all reported to be potential 
risk factors for ASD (Lyall et al., 2017). Also, combining these different exposures is very likely 
to increase probabilities to develop ASD (Lyall et al., 2017). 
 
 Recently, the environment of both parents before conception has been suggested to 
influence the development of the future embryo and lead to ASD phenotypes. Among other 
factors parental age, stress and life style can influence future embryonic development 
(Franklin et al., 2010). The current hypothesis suggests that environmental factors can induce 
epigenetic changes by altering parental genomic activity (changes in methylation of promoter 
regions) which can be transmitted across generations (Franklin et al., 2010; Saavedra-
Rodriguez and Feig, 2013).  
 
Several studies demonstrated that DNA methylation can change in response to 
environmental factors (Argos, 2015; Joubert et al., 2016) and epigenetic modifications can be 
inherited (Skinner, 2011). These findings highlight the importance to investigate further the 
epigenetic and genetic aspect of ASD. To date, it remains unclear what is the exact 
contribution of environmental versus genetic factors in ASD and to what extend gene-
environment interactions weight in the balance of developing the disorder. However, with the 
constant improvement of sequencing and genome wide association studies, considerable 
progress has been made in the field. 
 
1.2.4.2 Genetic risk factors 
 
In the late 1970s family and twin studies started to show the high heritability of ASD 
(Folstein and Rutter, 1977a; Ronald and Hoekstra, 2011). Today, ASD concordance rates 
between twins varies significantly across studies but ranges between 40-90% for monozygotic 
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twins and between 15-35% for dizygotic twins (Ronald and Hoekstra, 2011). In parallel, whole 
genome sequencing and whole-exome sequencing methods further identified a number of 
rare highly penetrant mutations leading to ASD (Geschwind and State, 2015). These studies 
clearly highlight the strong genetic contribution to the pathophysiology of ASD. 
 
Mutations can be either inherited or in rare cases arise “de novo” in the germline. ASD 
inheritance can occur in different ways : Autosomal recessive, both healthy parents carry one 
allele with a recessive mutation; Autosomal dominant, one parent carries a dominant 
mutation; X-linked, the mother carries the mutation on the X chromosome (higher risk for 
males to develop ASD); Additive mutations, addition of common genetic variations from both 
parents.  
 
Genetic mutations can arise in different ways, with a single nucleotide change up to an 
entire locus. Structural variation of genomic sections, also called copy-number variants (CNV) 
can be either deleted, duplicated or translocated. Alterations at the nucleotide level can 
create missense, frameshift, nonsense or trinucleotide repeat mutations. Gene expression can 
be altered either directly in the exonic and splice site regions creating a truncated protein or 
indirectly by affecting intronic regulatory regions.  
 
A good illustration of the genetic contribution to ASD, are rare de novo mutations; 
because they appear only in the germline of affected individuals and are not present in the 
parental genome. Monogenic syndromic forms of ASD usually show high penetrance 
(frequency with which a particular gene is associated with a given phenotype), ranging 
between 30-80%. One of the most highly penetrant gene (~80%) is the SHANK3 gene encoding 
for a synaptic scaffolding protein (Leblond et al., 2014). 
 
Even though single genetic mutations can be highly penetrant, they are found only in 
a small fraction of ASD population. Each risk gene is present in less than 1% of the affected 
individuals (see Figure 2). Rare de novo and inherited mutations only account each for ~3% of 
total screened individuals with ASD. Recently it has been suggested that most genetic risks 
seem to arise from common genetic variation; genomic regions commonly vary across 
individuals, including mostly polymorphism in single nucleotides (SNP). SNPs are common 
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base pair changes found in more than 1% of the population. These common variations have 
been recently proposed to potentially contribute to nearly 50% of ASD cases (Gaugler et al., 
2014). Thus, it has been hypothesized that polygenic variations might be the major risk for 
developing ASD. In other words, inherited variants each contributing to a small fraction, could 
together produce an additive risk for developing ASD.  
 
Therefore, identifying genetic risk factors is an essential step to further shape the 
genetic architecture of ASD. In the past years, major advances made in genome sequencing 
studies allowed the identifications of hundreds of new genes associated with ASD 
(www.sfari.org/resource/sfari-gene). Currently, advances in the field estimate the genetic 
etiology of ASD around 30%-50% (de la Torre-Ubieta et al., 2016). For the remaining 
percentage, it remains to be addressed if the environment, epigenetics, genetics or likely a 
combination of all will complete the puzzle. 
 
The following Figure adapted from de la Torre-Ubieta et al. (2016) summarizes the 
genetic aspects of ASD discussed in this section: 
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Figure 2. Genetic architecture of ASD (de la Torre-Ubieta et al., 2016). (a) Different inheritance 
pattern and their associated syndromic form of ASD. The red stars indicate a causal allele and the red 
pie charts indicate a small proportion of risk. (b) The types of genetic variations and the associated 
developmental disorders. (c) The penetrance of known syndromic mutations summarized from multiple 
studies. 95% binomial proportion confidence intervals, based on Wilson’s score interval. (d) The 
percentage of individuals with ASD harboring known mutations, as well as the percentage of liability 
from different classes of mutations. The percentage variance in liability measures the contribution of a 
particular variant or class of variants relative to the population variance in a theoretical variable called 
liability. Liability is a continuous and normally distributed latent variable that represents each 
individual’s risk (both genetic and environmental) for developing a disease. 
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Understanding the pathophysiology of ASD not only requires the identification of risk 
genes but also the study of their biological function. As described in section 1.2.3 a number of 
converging biological pathways have already been identified, however targeted molecular 
therapies can be considered only if convergent pathways are better defined.  
 
1.2.5 The importance of model systems  
 
Human brain surveys offer a limited number of biological information. Patient studies 
can only provide behavioral, metabolic and brain network information. Post-mortem tissues 
availability is generally limited and tissues are often genetically very heterogeneous. Thereby, 
system models are necessary to rigorously study the biological implications of risk genes. 
Mouse models are the main biological system used so far. The mouse genome can be targeted 
with genetic engineering tools to specifically alter a gene of interest and study the 
downstream effects. Mouse models offers a number of advantages: they share high genomic 
homology with humans, they reproduce fast with large litters, are cost-effective, offer 
reproducibility, genetic traceability and most importantly accessibility to molecular, cellular, 
circuit and behavioral experimentations. However, mice models also have some limitations. 
The evolutionary distance involves a number of biological differences, including poorly 
conserved regulatory elements, differences in the social circuitry and limitations in behavioral 
read-outs. 
 
Alternatively to mice models, human cells can be used to study ASD. Advances in stem 
cell biology made possible to culture human embryonic stem cells, human induced pluripotent 
stem cells (iPSCs) and primary human neural progenitors (Aigner et al., 2014). To model ASD, 
cells can either be cultured directly from patients (from surgery or post-mortem) or genetically 
targeted (with genetic engineering tools such as the CrispR-Cas9 system). Recently, a major 
advance in the field made possible long-term three-dimensional culture of iPSCs, giving rise to 
organoid brain like structures (Lancaster et al., 2013). This way, iPSCs can be isolated from 
ASD patient that underwent brain surgery (tissue removed from epileptogenic regions) and 
provide a good model system. Alternatively, targeted mutations can be induced as well in 
organoid cultures to model ASD (Pasca, 2018). 
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Mice, and more recently human in vitro models, provided most of the current 
knowledge regarding the biological understanding of ASD. Using model systems to study 
individual risk genes not only provides essential information on their function but also further 
shapes the complex pathophysiology of ASD.  
 
1.3 PTCHD1: a poorly understood risk gene for ASD 
 
1.3.1 Human PTCHD1 mutations are linked with ASD and ID 
 
In 2008, a genome-wide study comparing CNVs of 427 unrelated ASD patients to 500 
unaffected individuals, identified the Patched domain containing 1 (PTCHD1) locus as a risk 
factor for ASD (Marshall et al., 2008). Later, Pinto et al. (2010) confirmed this finding in a larger 
scale sequencing studies comparing 996 ASD cases to 1287 unaffected controls. Identified 
mutations were all CNV deletions inherited from mothers X chromosome. Similarly, Whibley 
et al. (2010) conducted a fine scale study focusing specifically on X chromosome linked 
intellectual disability (XLID). 251 cases diagnosed with XLID were analyzed with an X 
chromosome array platform. A 90 kb deletion spanning the entire PTCHD1 gene was identified 
in a family with XLID affected males across two generations (mutated allele carried by the 
unaffected grandmother). Subsequently, Noor et al. (2010) focused specifically on validating 
and characterizing the PTCHD1 CNVs and their inheritance in the families. They conducted a 
large scale meta-analysis on three ASD data sets (total: ASD N=1843, ID N=246, ADHD N=167, 
controls N=10896). The study validated with real-time quantitative PCR (RT-qPCR) the 
heritability of previously identified CNV deletions from Marshall et al., Pinto et al. and Whibley 
et al. Further, for 10 ASD cases deletions were mapped upstream of PTCHD1 coding region. 
This suggests a potential involvement of upstream regulatory element in PTCHD1 linked 
disorders. Finally six cases of point mutations in unrelated ASD families and two ID families 
were found, suggesting that truncations in the Ptchd1 protein are sufficient to trigger ASD or 
ASD like phenotypes. Findings from Noor et al. suggest that PTCHD1 mutations occur in ~1% 
of ASD cases, however this estimation has not been confirmed yet. Taken together these 
sequencing surveys indicate that PTCHD1 is a highly inheritable and penetrant risk gene 
strongly associated with ASD and ID. 
Introduction 
 36 
 
A clinical study by Chaudhry et al. (2015) documented the phenotypic alterations on 
23 PTCHD1 mutated individuals. All affected cases were males except one female. Clinical 
assessments were done at different ages but 18 out of 23 patients were evaluated before age 
13. As summarized in Figure 3, around 40-45% of them displayed either core or associated 
ASD symptoms, with a certain degree of overlap between conditions. In addition, several of 
them had motor delays and half of them displayed a hypotonic face, suggesting a potential 
involvement of PTCHD1 in muscular function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Prevalence of core and associated ASD symptoms in PTCHD1 muted individuals. 
Estimations were calculated from Chaudhry et al. (2015) on N=23 individuals. “Other psychiatric 
disorders” shown in green include anxiety, aggression, attention deficit, hyperactivity, depression. 
  
 
Overall, this survey suggests that all 23 individuals carrying PTCHD1 mutations were 
affected by either a neurodevelopmental, a cognitive and/or a psychiatric disorder. However, 
a larger study would be needed to confirm whether these estimations on 23 cases are 
representative. The main obstacles to perform such large-scale studies is finding patients 
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carrying the mutation of interest. Even if PTCHD1 mutations appear to occur at higher rate 
than most of the risk genes, they remain rare in the overall ASD population.  
 
Documenting the phenotypic outcomes of a single gene mutation is an essential step 
to link a gene with a pathology. However, this does not provide any information on how a 
gene mutation leads to downstream dysfunctions. This requires neurobiologists to focus on 
the gene product and its implications at a molecular, cellular, circuit and behavioral level. 
 
1.3.2 The PTCHD1 gene is predicted to produce a transmembrane protein 
 
The PTCHD1 gene is located on the X chromosome, composed by 13714 base pair with 
three exonic regions. It encodes for a 888 amino acid protein predicted to form a twelve pass 
transmembrane protein, as shown in Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic representation of the Ptchd1 protein. The twelve pass transmembrane protein 
carries a sterol sensing domain (SSD, shown in yellow) and a PDZ binding motif (shown in red) at the C-
terminal of the protein.   
 
 
As shown on Figure 4, Ptchd1 carries a sterol sensing domain (SSD) capable of binding 
sterols. In addition, the protein possesses a PDZ binding motif, a short C-terminal amino-acid 
motif that binds proteins carrying a PDZ domain. Proteins with PDZ domains are involved in 
scaffolding, transporting and organizing signaling complexes at the membrane, especially at 
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the synapse. These two components (SSD and PDZ binding motif) will be subject of different 
hypotheses and discussion later in this manuscript.  
  
As shown on Figure 5, PTCHD1 appeared early in eukaryotic evolution and displays very 
few changes within mammalians with around 95% average sequence identity (calculated with 
Uniprot alignment tool). Such high genetic conservation can suggest its implication in essential 
biological processes necessary for the survival of an organism.  
 
 
 
Figure 5. Gene tree of PTCHD1. (Modified from www.treefam.org). Left, Evolutionary genetic 
distances of PTCHD1 across species. Right, Percentage of amino acid identity to the human Ptchd1 
protein.  
 
 
PTCHD1 is the member of a family of three other “patched domain like” proteins: 
PTCHD2, 3 and 4. Compared to PTCHD1, these three proteins have very low or no expression 
in the brain (allenbrain data) and they have not been link with any neurodevelopmental 
disorder or disease. Moreover, a sequencing study showed no association between individuals 
with PTCHD3 mutations and ASD (Ghahramani Seno et al., 2011). 
 
1.3.3 Ptchd1 is hypothesized to be a Sonic hedgehog receptor 
 
The four “patched domain like” proteins carry this nomenclature because they share 
a SSD with the well characterized patched (Ptch) protein (Kuwabara and Labouesse, 2002). As 
shown in Figure 6, the SSD is highly conserved in six families of proteins:  
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(1) hydroxymethylglutaryl-CoA reductases (HMDHs), cholesterol biosynthetic enzymes 
degraded when sterol levels are high;  
(Andersen and Koeppe) SREBP (sterol regulatory element binding protein) cleavage activating 
proteins (SCAPs),  
(3) Niemann-Pick C-1 type protein (NPC1), an intracellular cholesterol transporter;  
(4) Dispatched proteins, involved in releasing the cholesterol-bound hedgehog;  
(5) Patched proteins, receptors of the morphogen factor sonic hedgehog (Shh);  
(6) Patched-related (or patched domain like) proteins. 
 
Figure 6. Phylogenetic tree of sterol sensing domains. Adapted from Strope et al. (2009). The 
maximum likelihood phylogenetic tree of 59 SSD regions. Six families of proteins clearly cluster 
separately. The Patched-related family cluster closely to the NPC1 and Patched family. The MAFFT tool 
was used for multiple alignment and the RAXML tool was used to reconstruct the phylogenetic tree. 
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As shown in Figure 6, Ptchd1 shares a highly conserved SSD primarily with the 
morphogen receptor Ptch and the cholesterol transporter NPC1. Shh, the ligand of Ptch, 
carries a sterol group that binds onto the SSD of Ptch and induces the inactivation of the 
transcription repressor Smoothend (Smo). Smo represses the activity of the GLI transcription 
factors. Thereby the binding of Shh onto Ptch will indirectly activate a number of GLI 
dependent transcriptional processes essential for correct morphogenesis and neuronal 
proliferation.  
 
Based on this well characterized pathway and sequence similarities, Noor et al. (2010) 
assessed if Ptchd1 could have a similar function than Ptch and thereby performed an in vitro 
GLI dependent reporter assay. The activity of a luciferase reporter dependent on GLI was 
measured in cells over expressing either Ptch1,2 or Ptchd1. Despite a number methodological 
inconsistency, the study concluded that similarly to Ptch1 and 2, Ptchd1 represses GLI 
dependent transcription in vitro. Based on this transcriptional reporter assay and the 
conserved  SSD, it was hypothesized that Ptchd1 may contribute to Shh signaling (Noor et al., 
2010). Until the beginning of my PhD project in 2014, this hypothesis had not been further 
investigated and the exact molecular function of Ptchd1 stayed unclear.  
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Note: Towards the completion of my PhD, two other studies contributed to the characterization 
of Ptchd1 (Wells et al., 2016; Ung et al., 2017). As this manuscript follows a chronological order 
to justify the aims of the project, the contribution of the two studies will be treated in the 
discussion part (section 3.) 
 
1.4 The dissertation project 
 
As introduced, dissecting the etiology of ASD by characterizing the function of risk 
genes is essential to identify convergent pathways and thereby find targeted molecular 
therapies. PTCHD1 is a highly penetrant and prevalent gene found in individuals with ASD and 
ID (Noor et al., 2010; Chaudhry et al., 2015).  The gene produces a twelve-pass transmembrane 
protein that shares a SSD domain with Ptch and NPC1 (Kuwabara and Labouesse, 2002; Noor 
et al., 2010). As described earlier, Ptchd1 was hypothesized to contribute to Shh signaling 
(Noor et al., 2010). In addition, a number of studies showed that alterations in the Pch-Shh 
pathway lead to severe deficits; Heterozygous or conditional homozygous mutations of Ptch 
result in Shh-independent activation of the signaling molecule Smoothened. Hyper-activation 
of Smoothened regulation results in neuronal precursor over-proliferation, enlargement of 
the external germinal layer of the cerebellum, and the development of medulloblastomas 
(Goodrich et al., 1997; Yang et al., 2008). Recent studies have identified Boc and Gas1 as 
obligate co-receptors for Shh signaling in the cerebellum. Their loss of function results in 
reduced Shh-dependent proliferation of precursors (Izzi et al., 2011) and cerebellar 
abnormalities. Given these well-documented functions of the Shh-Ptch1 pathway, we 
generated a knock-out mouse model to start examining whether neuronal precursor 
proliferation was altered in Ptchd1 knock-out (Ptchd1-/y) mice. This first hypothesis was 
embedded in a broader question asking what is the molecular and cellular function of Ptchd1 
in the brain. This question was the main driver of my project and set the following milestones: 
 
(1) Localize PTCHD1 expression in the brain at an anatomical and cellular level 
(2) Assess Ptchd1 involvement in the Shh pathway using a Ptchd1-/y mouse model 
(3) Identify Ptchd1 interacting partners 
(4) Characterize Ptchd1 function in vitro and in vivo with the loss of function model 
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2. Results 
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Note: The following results were published in the Journal of Neuroscience in November 2017: 
(Tora et al., 2017), except for section “2.7 Preliminary result”. The electrophysiological recording 
were done by Dr. Andrea Gomez and the in vitro Shh binding assay was done by Patricia T. Yam 
and Jean-Francois Michaud from the laboratory of Pr. Frédéric Charron. The text used in the 
result section is adapted from the publication, except for section 2.7, which is new unpublished 
data. 
 
2.1 Developmental regulation of Ptchd1 expression in the mouse brain 
 
To identify cell populations in the mouse brain with high Ptchd1 expression we used in 
situ hybridization with a probe directed against the 5’ UTR (exon 1) of mouse Ptchd1. In 
developing mouse brain (postnatal day 12), we observed significant hybridization signals 
across the entire brain with high signals in the thalamic reticular nucleus and the cerebellum. 
In the cerebellum, there was significant expression in the external germinal layer, a site where 
granule cell precursors proliferate before they initiate their migration towards the internal 
granular layer (Figure 7A). In adult mice (postnatal day 60) we found highest hybridization 
signals in the internal granular layer of the cerebellum, the reticular nucleus of the thalamus, 
and in the dentate gyrus of the hippocampus, consistent with a previous report (Wells et al., 
2016) (Figure 7B).  
 
Previous work reported synaptic deficits in the hippocampus of Ptchd1 mutant mice 
(Ung et al., 2017). Thus, we sought to obtain additional, more quantitative insights into Ptchd1 
expression in this brain area.  Fluorescent in situ hybridization with Ptchd1-specific probes 
revealed high Ptchd1 mRNA expression in dentate granule cells of 21 day old mice whereas 
expression in the CA1-3 pyramidal cells was very low (Figure 7C,E,F). Similarly, high 
hybridization signals were observed in the dentate gyrus of adult (P60) mice (Figure 7D).  
 
Quantitative PCR measurements for Ptchd1 mRNA across multiple brain areas 
confirmed broad expression and developmental regulation of the Ptchd1 transcript (Figure 
7G). In the cerebellum, there was a 2-3 fold up-regulation of Ptchd1 relative to Gapdh from 
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postnatal day 15-30 (Figure 7G, a similar up-regulation was observed when Hprt was used as 
a normalizer).  
 
To further confirm differential expression of Ptchd1 mRNA across the principal cell 
types of the hippocampal circuit we micro-dissected dentate gyrus and Ammon’s Horn from 
P21 mice and performed quantitative PCR analyses (Figure 7H). Again, we observed high 
expression of Ptchd1 mRNA in dentate gyrus and low expression in Ammon’s horn 
preparations. Together, these observations support significant expression of Ptchd1 mRNAs 
in the developing and adult brain, and particularly prominent expression in the thalamic 
reticular nucleus, hippocampal dentate granule cells, and cerebellar granule neurons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Results (Tora et al., 2017) 
 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Results (Tora et al., 2017) 
 47 
Figure 7. Ptchd1 mRNA distribution in the mouse brain. A, Ptchd1 in situ hybridization on mouse 
brain sagittal sections at post-natal day 12 (P12) with antisense (up) and sense probes (down). High 
magnification view of the developing cerebellum (right; EGL: external granule cell layer; ML: molecular 
layer; PCL: Purkinje cell layer; IGL: Internal cell layer). B, Ptchd1 in situ hybridization at P60 with with 
antisense (up) and sense probes (down). High magnification view of the dentate gyrus (Yang et al.). C, 
Fluorescent in situ hybridization of mouse P21 hippocampus with negative control probe set (left) and 
Ptchd1 probe set (Yang et al.). DAPI in blue; Ptchd1 mRNA in magenta. D, Fluorescent in situ 
hybridization of mouse P60 hippocampus with Ptchd1 probe set; nuclei stained with DAPI in blue; 
Ptchd1 mRNA in magenta. E, High magnification view of the dentate gyrus (DG), CA1 and CA3 of the 
hippocampus (P21 WT mouse coronal section). F, Quantification of fluorescent signal, measured as 
number of dots in whole DG, CA1 and CA3 area. (N=3 P21 mice, n=22 coronal sections both hemispheres 
analyzed; mean and SEM; student t-test). G, Quantitative RT-PCR assay of Ptchd1 mRNA expression 
levels during brain development and across different brain regions (N=3 mice per age, mean and SEM, 
one way ANOVA, Tukey's multiple comparisons test). H, Quantitative RT-PCR assay of Ptchd1 mRNA 
expression levels in micro-dissected dentate gyrus (DG) and Ammon’s horn (AH). TDO2 and DSP serve 
as control to confirm DG tissue enrichment. Mrg1b serves as control to confirm isolation of Ammon’s 
horn tissue (AH). (N=3 P21 mice, mean and SEM; Student t-test).  
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2.2 Ptchd1 knock-out mouse generation 
 
To examine essential functions of Ptchd1 we generated a conditional knock-out allele 
where exon 2 is flanked by loxP sites (Figure 8A). We then generated a germline Ptchd1 mutant 
(Ptchd1-/y) by crossing with Cre-deleter mice. Using RT-PCR we observed a loss of exon 2 
containing sequences and detected transcripts containing exon 1 sequences joined to exon 3 
(Figure 8B).  
 
Due to a frame-shift, these transcripts carry a translational stop codon 93 amino acids 
into exon 3, resulting in the loss of 9 of the 12 transmembrane-domains and disruption of the 
sterol-sensing domain of the Ptchd1 protein.  
 
To examine the impact of exon 2 deletion on Ptchd1 protein expression we raised 
polyclonal antibodies and probed Ptchd1 protein levels in Western blots. In transfected 
HEK293 cells, Ptchd1 antibodies specifically recognized EGFP-tagged Ptchd1 protein of 120 
kDa (Figure 8C). In mice, we detected a 95kDa protein in lysates from adult mouse wild-type 
hippocampus and cerebellum that was absent in male Ptchd1-/y mice (Figure 8D). Using the 
same antibody, we further confirmed broad Ptchd1 protein expression as well as high 
expression in the mouse cerebellum (Figure 8D). 
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Figure 8. Ptchd1 knock-out mouse generation and validation. A, Ptchd1 knock-out strategy, the 
Ptchd1 gene was modified by replacing exon 2 with cassette containing a gene trap lacZ-Neo cassette 
(engrailed 2 splicing acceptor) flanked by Frt sites and additional loxP sites flanking Exon 2. Conditional 
Ptchd1 floxed animals were obtained by breeding to Flip deleter mice, resulting in an excision of the 
trap cassette. The Ptchd1 knock-out allele was generated by crossing Ptchd1 floxed animals with 
CMVcre deleter mice. B, RT-PCR of WT and Ptchd1-/y cDNA; shows successful removal of Exon 2 and 
splicing of exon 1 into exon 3, resulting into a frame-shift. Splice junctions were confirmed by DNA 
sequencing.  C, Specificity of a Ptchd1-specific antibody was confirmed by Western blot analysis of 
HEK293T cells overexpressing a Ptchd1-EGFP fusion protein. D, Successful ablation of Ptchd1 protein in 
knock-out animals was verified by Western blot analysis of hippocampal tissue lysate (left) and 
cerebellar tissue lysate (middle). Right, Ptchd1 protein relative expression levels across brain regions in 
adult P60 mouse. Similar results were obtained in 3 independent experiments. 
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2.3 Proliferation of neuronal precursors in Ptchd1-/y mice 
 
Ptchd1 has been suggested to act as a Shh receptor (Noor et al., 2010). During early 
postnatal development, cerebellar granule cell precursors proliferate in response to Purkinje 
cell-derived Shh (Wechsler-Reya and Scott, 1999) and homo- or heterozygous knock-out of 
the Shh receptor Patched 1 (Ptch1) results in granule cell precursor over-proliferation 
(Goodrich et al., 1997; Yang et al., 2008). Given the high expression of Ptchd1 in granule cell 
precursors during early postnatal development we tested whether precursor proliferation was 
altered in Ptchd1-/y mice.  
 
We injected mice at postnatal day 4 (P4, a time where Shh-dependent proliferation is 
high) with 100mg/kg BrdU and then probed the number of BrdU-positive cells 30 mins after 
injection. Using this protocol, the density of BrdU-positive cells as well as the density of cells 
immuno-positive for the proliferation marker phospho-histone 3 (PH3) were unchanged in 
Ptchd1-/y mice (Figure 9A,B).  
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Figure 9. Proliferation of neuronal precursors in developing Ptchd1-/y mice. A, Wild-type (WT) and 
Ptchd1-/y (KO) mice were injected with 100mg/kg  BrdU at postnatal day 4 (P4) and analyzed 30 mins 
later. Cerebellar sections were stained for BrdU, PH3 and DAPI. B, Quantification of BrdU- and PH3-
positive cell density in the EGL. Cell counts are normalized to the EGL area. Mean and standard deviation 
from N=5 mice per genotype; n= 65 Ptchd1-/y, 61 WT sections (light dots); solid dots are means of cell 
density per animal; unpaired t-test. C, Hippocampal sections of P4 WT and Ptchd1-/y (KO) mice stained 
for BrdU, DAPI. Insets show enlargements of the area marked with a dashed box. D, Quantification of 
BrdU and PH3-positive cell density in the DG. Cell density was normalized to the DG area. Mean and 
standard deviation, from N=5 mice per genotype; n= 61 Ptchd1-/y, 61 WT sections (light dots); solid dots 
are means of cell density per animal; unpaired t-test. 
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A second neuronal precursor population that is dependent on Shh signaling during 
development are granule cells in the dentate gyrus of the hippocampus (Han et al., 2008; Li et 
al., 2013). Thus, we quantified BrdU- and PH3-positive cells in wild-type and Ptchd1-/y mice. 
Similar, to the cerebellum, BrdU-incorporation and density of PH3-positive cells was not 
significantly changed (Figure 9C, D).  We then tested BrdU incorporation in adult (P60) dentate 
gyrus since Shh has also been implicated in the maintenance of adult neural stem cells in this 
area (Lai et al., 2003).  However, in Ptchd1-/y mice we did not detect a significant change in the 
density of PH3 or BrdU-positive cells 4 days after BrdU injection (Figure 10A, B).  
 
Our results thus far suggest that the absence of Ptchd1 has no dramatic effect on 
neuronal precursor proliferation in vivo in cell populations that undergo Shh-dependent 
proliferation. To directly determine if Ptchd1 may interact with Shh, we tested whether Shh 
can bind in vitro to cells expressing Ptchd1 protein.  
 
We observed robust binding of Shh to COS7 and mouse embryonic fibroblast (MEF) 
cells expressing Ptch1 but no binding to cells expressing Ptchd1 nor NPC1 under identical 
experimental conditions (Figure 10C). Thus, 50% of COS7 cells and 78% of MEFs expressing 
Ptch1 exhibited clearly recognizable Shh surface binding whereas none of the cells expressing 
Ptchd1, GFP or NPC1 did (Figure 10D). In aggregate, these experiments suggest that 
expression of Ptchd1 is not essential for the Shh-dependent proliferation or maintenance of 
neuronal precursors in the developing cerebellum or the postnatal dentate gyrus. 
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Figure 10. Adult neurogenesis in Ptchd1-/y mice and Shh binding to Ptchd1. A, Wild-type (WT) and 
Ptchd1-/y (KO) mice were injected with 100mg/kg BrdU at postnatal day 60 (P60) and analyzed 4 days 
later (P64). Hippocampal sections of WT and Ptchd1-/y (KO) mice were stained for the DAPI (blue), BrdU 
(Pinto et al.) and PH3 (red). Insets show enlargements of the area marked with a dashed box. B, 
Quantification of BrdU- and PH3-positive cell density in the sub-granular zone (SGZ) of the dentate 
gyrus. Cell numbers were normalized to SGZ length. Mean and standard deviation. n=156 Ptchd1-/y, 160 
WT dentate gyrus regions analyzed (light dots) from N=5 mice per genotype (solid dots are means of 
cell density per animal), unpaired t-test. C, Sonic hedgehog (Shh) binding assay on COS cells over-
expressing either Ptch1-GFP, NPC1-GFP or Ptchd1-GFP fusions. GFP expression, Shh-Fc immunostaining 
and DAPI. D, Quantification of Shh-Fc binding to COS7 cells (N≥103 cells) and to MEF cells (N≥40 cells). 
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2.4  The Ptchd1 cytoplasmic tail interacts with scaffolding proteins and the 
retromer complex 
 
Ptchd1 is predicted to form a twelve pass transmembrane protein with a PDZ-binding 
motif at the C-terminal tail (Figure 11A). To identify proteins that may contribute to Ptchd1 
localization or function we performed affinity-purifications from whole brain extracts with the 
43 amino acid cytoplasmic C-terminus of Ptchd1 either constitute (WT) or lacking (DPDZ) the 
last 4 residues that contain the PDZ-binding motif. As a negative control, we used a protein 
containing an extracellular sequence of Ptchd1 (ECD, see Figure 11A, B).  
 
Proteins retained on hexa-histidine-GST-fusions of these baits were identified by shot-
gun mass-spectrometry and specificity of the interaction was assessed by comparison to the 
ECD control protein (Figure 11C, D; complete mass-spec data online in supplementary Figure 
5-1). Quantitative analysis identified a number of proteins that were enriched on the wild-
type C-terminus whereas other candidate binding partners were enriched on both, wild-type 
and DPDZ tails. Twelve out of thirteen proteins preferentially recovered on the wild-type 
Ptchd1 tail compared to the DPDZ mutant contained PDZ-domains, including common 
components of the postsynaptic density (Dlg1,2,3,4, Magi1,3, Lin7).  
 
Interestingly, we recovered three components of the retromer complex involved in 
regulating dendritic protein trafficking between endosomal compartments and the plasma 
membrane (Choy et al., 2014): Sorting-nexin 27 (which contains a PDZ domain) was recovered 
selectively on the wild-type Ptchd1 tail and VPS26B and VPS35 which interacted with both the 
wild-type and the DPDZ tail.   
 
In addition, there was a notable number of ribosomal proteins recovered both on wild-
type and DPDZ bait proteins (RL5, 7, 8, 18A, 27, 31, 32,37, Rpl31). Whether these ribosomal 
proteins represent physiological binding partners or whether they are non-specifically 
recruited through the stretch of highly charged amino acids in the Ptchd1 cytoplasmic tail 
remains to be explored.  
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Using Western blotting, we validated our mass spectrometry approach confirming the 
binding of Dgl4 (also known as PSD95) and VPS35 to the recombinant Ptchd1 C-terminus. 
Thus, endogenous DLG4 and VPS35 from membrane and soluble mouse brain fractions were 
specifically recovered on the GST-fusion proteins containing the cytoplasmic but not the 
extracellular, negative control sequences of Ptchd1 (Figure 11E). Notably, binding of DLG4 was 
dependent on the PDZ-binding motif in Ptchd1 whereas VPS35 binding was not (Figure 11E). 
  
 Considering the association with post-synaptic density proteins and retromer, we tested 
whether endogenous Ptchd1 protein is concentrated in postsynaptic density-preparations 
from mouse brain. Synaptosome fractionations revealed an enrichment of Ptchd1 in the PSD 
obtained from adult mouse brain (Figure 11F, Ptchd1-/y brains were analyzed to control for 
antibody specificity). These results demonstrate a biochemical interaction of Ptchd1 with 
postsynaptic trafficking proteins in the mouse brain. 
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Figure 11. Ptchd1 cytoplasmic tail interacts with scaffolding proteins and retromer complex.  
A, Schematic representation of predicted Ptchd1 protein topology. B, Three recombinant hexahistidin-
glutathion-S-transferase (Joubert et al.) fusion proteins used for the pull-down analysis: WT: Ptchd1 C-
terminal sequence (Pinto et al.), ΔPDZ: C-terminal lacking the predicted PDZ binding motif (orange), and 
ECD: negative control sequence from the first extracellular loop of the Ptchd1 (blue). C, Quantitative 
shotgun mass spectrometry data of proteins recovered in Ptchd1 pull-down assays using a soluble brain 
membrane fraction as input. D, Quantitative shotgun mass spectrometry data of proteins recovered in 
Ptchd1 pull-down assays using a soluble brain protein fraction as input. All proteins identified with at 
least 3 peptides, 400 spectra counts, and enriched at least 4-fold on the wild-type Ptchd1 bait as 
compared to the negative control (His-GST-ECD) are displayed. The graphs show enrichment (log2 ratio) 
compared to the ECD fraction (n=3 purifications, each measured in duplicate). The complete data from 
the mass-spec analysis is shown in the extended data Figure 5-1 (online version). E,F Validation of 
Ptchd1-DLG4 (PSD95) and Ptchd1-VPS35 interaction by western blotting. Ptchd1 interacting proteins 
were isolated by GST pull-down with ECD, WT and ΔPDZ baits from adult mouse membrane fractions or 
soluble brain protein extracts. The lower panel shows the respective protein fractions of the pull-down 
assay labeled with Coomassie dye. G, Synaptosome preparation from WT and Ptchd1-/y brains probed 
with Ptchd1, Dlg4/PSD95, and vGlut1 antibodies. 20 µg of total protein analyzed from total lysate, 
cytosolic, synaptosome, TritonX-100 soluble synaptosome and TritonX-100 insoluble synaptosome 
(PSD) fractions. Molecular weight markers are indicated in kDa.   
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2.5 Loss of Ptchd1 disrupts synaptic transmission in the dentate gyrus 
Given the high expression of Ptchd1 in dentate granule cells and its association with 
the post-synaptic density proteins we tested whether the density and differentiation of 
glutamatergic spine synapses might be altered in the hippocampus of Ptchd1-/y mice. Dentate 
granule cells in perfusion-fixed tissue from adult and P21 Ptchd1-/y mice were labeled by 
diolistics (Gan et al., 2000), then spine density and morphology were assessed (Figure 12A, B). 
Using this approach, we did not detect any difference in the overall density of dendritic 
protrusions in Ptchd1-/y neurons (Figure 12B). Further, the fraction of headed, spine-like 
protrusions was unaltered (Figure 12B). Thus, Ptchd1 is dispensable for the formation of 
dendritic spines in dentate granule cells at P21 and in adult mice.  
  
To determine if Ptchd1 enrichment in dentate granule cells is associated with synaptic 
dysfunction, we examined synaptic transmission using whole-cell recordings in acute 
hippocampal slices from P21-24 mice. Excitatory and inhibitory postsynaptic currents (EPSCs 
and IPSCs) were evoked by stimulation of the perforant pathway (Figure 12C). Interestingly, 
Ptchd1-/y dentate granule cells exhibited a profound reduction in the excitation/inhibition 
ratio (Figure 12D). AMPAR:NMDAR ratios and paired-pulse ratios of evoked glutamatergic 
transmission were unchanged (Figure 12E,F).  
 
We hypothesized that the reduced excitation/inhibition ratio may be caused by an 
increase in inhibition or a decrease in excitation, thus we examined basal activity by measuring 
spontaneous EPSCs or IPSCs. Surprisingly, we observed a significant increase in the frequency 
of both spontaneous excitatory and inhibitory events in Ptchd1-/y dentate granule cells (Figure 
12G,H). Together, these data suggest that loss of Ptchd1 results in severe alterations in 
synaptic function in the dentate gyrus. 
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Figure 12. Morphology and physiology of dentate gyrus granule cells in Ptchd1-/y mice.  
A, Diolistic labeling (red) of a hippocampal dentate granule cell in a P21 Ptchd1-/y (KO) mouse (DAPI 
labeling of nuclei in blue). The lower panels show an example of a P21 WT and KO DG granule cell distal 
dendrite. B, Spine density (per 30 µm dendrite segment) and morphology (headed versus non-headed 
spines) were quantified for P21 and adult (P60) wild-type and Ptchd1-/y (KO) mice. Means of 4 WT and 
4 Ptchd1-/y (P21) and 4 WT and 5 Ptchd1-/y (P60) mice are displayed (lines and solid dots); mean and 
unpaired Student t-test. The light dots represent values for individual dendritic segments scored (P21: 
Ptchd1-/y n=44, WT n=44; P60: Ptchd1-/y n=49, WT n=42). C, The schematic shows the configuration of 
whole-cell voltage-clamp recordings made from acute hippocampal slices of P21-P24 mice. Postsynaptic 
responses in granule cell (GC) neurons were measured following stimulation of the perforant pathway 
(pp). D, Representative traces of evoked EPSCs and IPSCs recorded from granule cells in acute 
hippocampal slices show disrupted excitation/inhibition balance in Ptchd1-/y (KO), granule cells (WT, 
n=10; KO, n=17; N=3 animals for each genotype; mean and SEM, unpaired t test). E Representative 
traces of evoked EPSCs used to calculate AMPAR/NMDAR ratios (WT, n=17; KO, n=18; N=3 animals for 
each genotype, unpaired t test) F, Normalized evoked postsynaptic responses of WT or Ptchd1-/y GC 
neurons to five stimuli delivered to the pp with a 50 inter-stimulus interval, The facilitation ratio of the 
2nd EPSC amplitude normalized to the 1st EPSC amplitude shows normal facilitation across various inter-
stimulus intervals in Ptchd1-/y (KO) GC neurons (Stimulus: 3rd/1st, p=0.18; 4th/1st, p=0.43; 5th/1st, p=0.64; 
WT, n=8; KO, n=16; N=3 animals for each genotype, two-way repeated measures ANOVA with multiple 
comparisons).  G, Representative traces of spontaneous EPSCs from wild-type or Ptchd1-/y GC neurons 
which were voltage-clamped at –70 mV, sEPSC frequency (WT, 0.22±0.04 Hz; KO, 0.39±0.04 Hz) but not 
sEPSC amplitude (WT, 0.22±0.04 Hz; KO, 0.39±0.04 Hz) is increased in Ptchd1-/y GC neurons (WT, n=10; 
KO, n=16; N=3 animals for each genotype, unpaired t test). H, Representative traces of spontaneous 
IPSCs from wild-type or Ptchd1-/y GC neurons which were voltage-clamped at 0 mV., sIPSC frequency 
(WT, 0.53±0.09 Hz; KO, 1.56±0.3 Hz) but not sIPSC amplitudes (WT, 14.72±0.67 pA; KO, 18.35±1.57) is 
significantly increased in Ptchd1-/y GC neurons (WT, n=10; KO, n=15; N=3 animals for each genotype, 
unpaired t test).  
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2.6 Ptchd1-/y mice show deficits in hippocampus-related behavioral tasks  
 
Considering the alterations in synaptic transmission we further explored behavioral 
phenotypes in our new line of Ptchd1 knock-out mice. In open field tests, Ptchd1-/y mice 
covered the same distance as littermate controls, however, the mutants frequently exhibited 
bouts of high mobility, largely due to jumping behaviors (Figure 13B). We then used an object 
recognition test, which in part depends on hippocampal function (Cohen and Stackman, 
2015). Animals are exposed to novel and familiar objects in a test arena. The time exploring 
the objects is scored 1hr and 24 hrs after the initial exposure. While wild-type mice showed a 
clear preference for novel over familiar objects we observed a marked loss of short term (1hr) 
and long-term (24hr) memory in Ptchd1-/y mice (Figure 13C). Notably, the mean object 
interaction time during the first (acquisition) trial was the same for wild-type and mutant mice 
(Figure 13D). During the re-test, wild-type mice showed decreased interaction with the 
familiar object and preference for the novel object. By contrast, Ptchd1-/y mice did not exhibit 
significant habituation to the familiar object in the 1 hr or 24 hr re-test (Figure 13D), thus, 
resulting in a lack of discrimination of novel and familiar stimuli. These results indicate a 
cognitive deficit in this line of Ptchd1-/y mice. 
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Figure 13. Ptchd1-/y  mouse behavioral analysis. A, Open field track visualization of a KO and a WT 
mouse. B, Distance traveled in the open field arena and high mobility state (N=9 Ptchd1-/y, N=5 WT), 
mean, unpaired t-test. C, Interaction time and discrimination ratio between familiar object and novel 
object presented 1hr and 24h after initial exposure (N=10 Ptchd1-/y N=8 WT), paired t-test. D, 
Habituation curve to familiar object over time (N=10 Ptchd1-/y, N=8 WT), mean and SEM, two-way 
ANOVA. 
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2.7 Preliminary result: Ptchd1-/y mice show alterations in brain lipid  
homeostasis 
 
Our work suggests that Ptchd1 is not a Shh receptor despite sequence homologies with 
Ptch. As described previously, Ptchd1 and the cholesterol transporter NPC1 also share sterol 
sensing domains. NPC1 dysfunction causes lysosomal cholesterol accumulation resulting in a 
severe neurodegenerative disorder. Thus, we hypothesized that Ptchd1 may be involved in 
lipid homeostasis and explored potential lipid alterations in Ptchd1-/y mice using an unbiased 
lipidomic approach. This work was done recently in collaboration with Howard Riezman’s 
laboratory, University of Geneva. The cerebellar tissue was chosen for the analysis as it shows 
highest Ptchd1 expression (Figure 7) . Lipids were isolated from KO and WT cerebellum and 
quantified using mass spectrometry. As shown on Figure 14A a number of lipids are 
significantly either down or upregulated in KO animals (red dots). Glycerophospholipids (GPLs) 
show the most important alteration (Figure 14B), including glycerophospho-serine (PS) / -
ethanolamine (PE) / -choline (PC). Interestingly, three lyso-glycerophospho-serine (lyso-PS) 
isoforms, metabolic intermediates of PS, are among the most downregulated lipids whereas 
PS (with six isoforms) are significantly upregulated. This differential alteration in the PS 
synthesis pathway could suggest a potential involvement of Ptchd1 in the biosynthesis or 
degradation of PS. Two other families of lipids are significantly down regulated: Ceramides 
(CMs) (nine isoforms downregulated out of fourteen detected) and sphingomyelins (SMs). 
This result suggest a potential involvement of Ptchd1 in lipid homeostasis however more 
samples and replications are under analysis to consolidate this promising finding. 
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Figure 14. Brain lipid changes in Ptchd1-/y mice. A, overall view of lipid changes in KO over WT mice, 
significant changes are shown in red (log10(p<0.05)); (N=4 Ptchd1-/y N=4 WT), paired t-test. B, 
Significantly changed lipids in KO samples (p<0,05). Different lipid classes, including their metabolic 
intermediates, are color coded as shown at the bottom of the graph. (N=4 Ptchd1-/y N=4 WT), paired t-
test. 
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3. Discussion 
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3.1 Loss-of-function experiments do not support a role in sonic-hedgehog 
signaling 
 
In this study, we generated and characterized a new Ptchd1 knock-out mouse line to 
explore the cellular and molecular functions of the Ptchd1 protein. An important goal of our 
work was testing whether loss of Ptchd1 results in Shh signaling-related phenotypes in vivo. 
The hypothesis that Ptchd1 acts as a Shh receptor is based on the presence of a sterol-sensing 
domain and reporter assays where exogenous Ptchd1 was overexpressed (Noor et al., 2010).  
 
A major function for Shh-Ptch1 signaling in the postnatal brain is the control of 
neuronal precursor proliferation in the developing cerebellum, in developing dentate granule 
cells and in adult neural precursors in the dentate gyrus. Thus, we tested precursor 
proliferation and maintenance in the hippocampal dentate gyrus and the external germinal 
layer of the cerebellum. However, we did not observe significant changes in Ptchd1 mutants. 
It is possible that the presence of Ptch1 compensates for a loss of Ptchd1, thus, obscuring a 
potential phenotype.  
 
We consider this unlikely for the following reasons: (1) Heterozygous deletion of Ptch1 
results in precursor over-proliferation and medulloblastomas in the mouse cerebellum, 
indicating that even partial loss of Ptch1-signaling results in severe Shh-related phenotypes. 
(Andersen and Koeppe) We did not observe binding of recombinant Shh to Ptchd1 under 
conditions where an interaction with Ptch1 was readily detectable. Notably, Ptchd1-like 
proteins are also found in non-mammalian species, including C.elegans which do not encode 
recognizable Shh orthologues in their genomes (Consortium, 1998). Thus, we favor the 
interpretation that Ptchd1 has different, Shh-independent functions in the developing and 
adult mouse brain.  
 
3.2 Ptchd1 binding partners support a role in the retromer trafficking 
complex 
 
Our unbiased proteomic approach identified PDZ-domain containing scaffolding 
molecules including synaptic scaffolding proteins. This was expected due to the C-terminal 
  Discussion 
 69 
consensus sequence –ITTV for PDZ domain interactions. In addition, we discovered an 
unexpected interaction with the retromer complex consisting of VPS35, VPS26B and SNX27.  
Notably, SNX27 contains a PDZ-domain and its interaction depends on the C-terminal 
PDZ-binding motif of Ptchd1. However, VPS35 and VPS26B were also recovered on the DPDZ 
bait protein, highlighting multiple interactions sites for Ptchd1 and the retromer complex. 
SNX27 as well as VPS35 have been implicated in membrane protein trafficking between 
dendritic endosomes and the plasma membrane, in particular postsynaptic glutamate 
receptors and b-adrenergic receptors (Wang et al., 2013; Choy et al., 2014). Thus, retromer 
may be involved in trafficking of Ptchd1 between endosomal and cell surface compartments 
including the postsynaptic compartment.  
 
3.3 Synaptic alterations in Ptchd1-/y mice 
 
Supporting a link to synaptic trafficking proteins, we observed a critical role of Ptchd1 
to the excitatory/inhibitory balance in dentate granule cells. The frequency of spontaneous 
excitatory as well as inhibitory events in dentate granule cells was increased. Previous work 
by Wells et al. (2016) demonstrated alterations in SK channel activity in somatostatin-positive 
interneurons in the thalamus. Thus, the alterations in spontaneous excitatory and inhibitory 
events in the dentate gyrus may result from Ptchd1-dependent phenotypes in glutamatergic 
as well as GABAergic interneurons. Dissecting the cellular and/or synaptic source of this 
electrophysiological phenotype will require conditional ablation of Ptchd1 from specific cell 
populations in the dentate gyrus.  
 
In  Ptchd1-/y dentate gyrus we did not observe alterations in facilitation ratios at 
glutamatergic synapses or loss of postsynaptic spine structures. This was surprising, as a 
recent report indicated a 33% reduction in excitatory synapse density in Ptchd1-/y 
hippocampus (Ung et al., 2017). One difference in our study is the focus on dentate granule 
cells which express the highest level of Ptchd1 mRNA in the hippocampus. By contrast Ung et 
al. focused on the CA region which according to our expression analysis expresses only very 
low levels of Ptchd1 transcripts. Another difference between the studies is the mutant allele 
employed. Similar to Wells et al. (Wells et al., 2016) we used a germline deletion of exon 2. 
Ung et al. used a mutant allele where exon 2 is replaced with a gene trap cassette (Ung et al., 
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2017). However, we consider it more likely that there is a differential requirement for Ptchd1 
in synapse development across cell types with high and low Ptchd1 expression levels such as 
dentate granule and CA1 cells. Moreover, some phenotypes may emerge as secondary effects 
due to functional alterations in upstream circuit elements. Analysis of conditional mutants 
may resolve this in the future. As the endogenous subcellular localization of Ptchd1 is still 
uncertain (due to the lack of good tools), it remains unclear whether the synaptic deficits are 
a consequence of Ptchd1 requirement directly at the synapse or rather in endosomes 
trafficking (as suggested by the pull-down assay). 
 
3.4 Behavioral alterations in Ptchd1-/y mice 
 
A survey of 23 subjects with PTCHD1 mutations reported intellectual disability, ASD, 
and motor alterations as phenotypes that are shared across significant sub-groups of these 
patients (Chaudhry et al., 2015). Moreover, several patients exhibit ADHD and hyperactivity. 
The increase in high mobility bouts and jumping of our Ptchd1-/y mice observed in open field 
assays is reminiscent of the hyperactivity phenotype reported previously for additional mouse 
models (Wells et al., 2016; Ung et al., 2017). Conditional ablation of Ptchd1 in somatostatin-
positive interneurons replicates the ADHD and hyperactivity phenotype of the mice but did 
not replicate learning deficits seen for global knock-out mice in an inhibitory avoidance task 
(Wells et al., 2016). The defect in objection recognition memory identified in our mouse line 
highlights a further cognitive deficit in this rodent model. Future work aims to illuminate 
whether this defect is due to hippocampal dysfunction. Taken together our work suggests that 
behavioral deficits in Ptchd1-/y mice are likely to be independent of changes in neuronal 
precursor proliferation or cell fate but rather alterations in post-mitotic neurons including 
deficits in synaptic transmission. 
 
3.5 Contribution of Ptchd1 to lipid homeostasis  
 
In addition to the Patched family, Ptchd1 also shares a conserved SSD domain with a 
number of protein families implicated in lipid homeostasis (Figure 6), one of the most 
phylogenetically similar protein to Ptchd1 is NPC1. In addition of causing cholesterol 
accumulation in lysosomal compartments, NPC1 deficient cells also show alterations in a 
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number of other lipid classes including glycerophospholipids and SMs (Lloyd-Evans et al., 
2008; Tharkeshwar et al., 2017). GPLs are the most abundant lipid class in mammalian cells, 
present intracellular as well as plasma membranes. Cholesterol and SMs are enriched at the 
plasma membrane and contribute to the formation of domains that can affect the signaling 
and distribution of membrane proteins (Coskun and Simons, 2010). Similarly, even if less 
abundant, CMs are thought to be important modulators of cell signaling (Hannun and Obeid, 
2008). 
 
Our preliminary data indicates that several GPLs are down regulated in Ptchd1-/y 
animals including PE, PC and PS precursors. Intriguingly, PS are upregulated in Ptchd1-/y brains 
whereas lyso-PS, metabolic intermediates of PS, are among the most downregulated lipids. 
Cholesterol levels in KO samples trend towards a downregulation (data not shown) but 
significance was not reached due to high variability across samples (more samples are under 
analysis to consolidate the data).  
 
The lipidomic approach appears to be an excellent tool to detect overall brain lipid 
dysregulations, however due to heterogeneity of altered lipids it remains unclear whether one 
class of lipid is specifically altered in Ptchd1-/y mice and leads to the alteration of others or if 
several lipids are affected directly by the absence of Ptchd1. The biosynthesis of different lipid 
classes can dependent on one another, for example PCs are precursors of PE and PS. Also, 
most lipids are synthesized in the endoplasmic reticulum (Fagone and Jackowski, 2009) and 
transported via similar pathways, mostly by endosomal/lysosomal transport. Thereby, if an 
alteration occur in one class of lipid it can trigger a cascade of alterations in other lipids, either 
directly with the lack of metabolic precursors or indirectly by affecting the entire lipid 
transport machinery.  
 
In addition, the integrity of the plasma membrane is important for the function of 
certain ion channels (Dart, 2010). Neuronal plasma membranes includes lipid micro-domains 
(also called “raft”) enriched with cholesterol and sphingolipids. These lipid rafts are suggested 
to regulate ion channels kinetics in neurons either directly through lipid-channel interaction 
(Jiao et al., 2008; Fantini and Barrantes, 2009) or indirectly through the rafts physical 
properties influencing channel surface expression and trafficking (Andersen and Koeppe, 
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2007). Given that Wells et al. (2016) reported alteration in SK channel in TRN interneurons of 
Ptchd1-/y mice, one interpretation to their observation could be that the dysfunction of SK 
channels is a consequence of lipid homeostasis modification in Ptchd1-/y animals. 
 
Also, it remains puzzling how sterols sensed by the SSD of Ptchd1 would regulated 
other classes of lipids. As suggested by the retromer proteins (VPS35/VPS26) recovered on the 
cytoplasmic tail of Ptchd1, the protein is likely to localize, at least transiently, in endosomal 
membranes. Endosomes are important effectors of the lipid turn-over machinery (Holthuis 
and Levine, 2005). Thus, if Ptchd1 acts as a sterol sensor and/or transporter, its absence may 
lead to sterol mislocalization and potentially create an endosomal lipid imbalance leading to 
the alteration of other lipids homeostasis. More targeted experiments aim to illuminate what 
subcellular compartments and machinery are affected. If lipid deficits are confirmed by future 
work, dietary and pharmacological strategies could be considered for ameliorating lipid 
alterations in Ptchd1 deficient patients. 
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4. Future directions 
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4.1 Is Ptchd1 part of the retromer trafficking complex ? 
 
Our unbiased proteomic analysis of Ptchd1 binding partners revealed interactions with 
three components of the retromer pathway: VPS35/VPS26 and SNX27. The retromer complex 
recycles endocytosed protein form endosomes to the plasma membrane or to the trans golgi 
network (TGN) (Seaman, 2012). However, SNX27 was shown to mediate retromer trafficking 
of cargoes from endosomes to the plasma membrane rather than the TGN in mammalian cells 
(Temkin et al., 2011). In addition, the retromer complex have been recently implicated in the 
trafficking of dendritic endosomes and the plasma membrane, in particular postsynaptic 
glutamate receptors and b-adrenergic receptors (Wang et al., 2013; Choy et al., 2014). Given 
these lines of research, one hypothesis would be that Ptchd1 is being transported via the 
retromer pathway between endosomes and the plasma membrane. 
 
Knowing in what subcellular compartment Ptchd1 localizes would greatly contribute 
to interpret its link with the retromer. Unfortunately, due to the lack of good tools, the sub-
cellular localization of Ptchd1 remains unclear. However, considerable efforts are ongoing to 
generate an efficient tool to visualize the protein; the aim is to generate a mouse line 
expressing a fluorescently tagged Ptchd1 (split-NeonGreen line) suitable for live imaging 
studies (see Appendix 6.1).. The live tracking of Ptchd1 would help understand the dynamic 
distribution of Ptchd1 in cells, especially in neurons. This could be combined with co-
localization assays using antibodies against VPS35/26, SNX27, endosomal markers (Rab5, 
Rab7) and lysosomal markers (Lamp1).  Identifying in which cell compartment Ptchd1 localizes 
is an essential step to understand its molecular function. 
 
 Alternatively, given the binding of Ptchd1 with retromer components, the absence of 
the protein in KO mice could alter the retromer pathway. One key aspect of the retromer 
pathway is the internalization of plasma membrane proteins into early endosomes, then 
further processed in late endosomes and lysosomes (Seaman, 2012). Several methods can be 
used for live imaging endosomal processing. One well established method is the incorporation 
of lipophilic fluorescent dyes (FM-dye) to cell culture media. Due to their lipophilic properties, 
the FM-dyes will incorporate into plasma membranes and internalized in endosomes, allowing 
the visualization of endosomal trafficking by fluorescent microscopy. Alternatively, some 
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endocytic tracers target specifically subpopulation of endosomes (early and late) or 
lysosomes. A widely used method is the usage of fluorescent pH sensitive probes conjugated 
to dextran. Early endosomes have a pH in the range of pH 6.8-6.1, late endosomes in the range 
of pH 6.0-4.8 and lysosomes around pH 4.5; certain probes emit fluorescence only in a specific 
pH ranges and can be used to label specifically sub-population of endosomes or lysosomes 
(Tharkeshwar et al., 2017). These well-established assays could be used in Ptchd1-/y neuronal 
cultures to assess whether or not the endosomal trafficking is perturbed in the absence of 
Ptchd1. Overall, given the potential implication of Ptchd1 in lipid homeostasis, it is not 
excluded that Ptchd1 transports or senses lipids via the retromer pathway. Future work aims 
to confirm lipid deficits observed in Ptchd1-/y animals and assess whether or not this deficit is 
dependent on retromer trafficking. 
 
4.2 Is Ptchd1 involved in lipid trafficking ? 
 
Our unbiased lipidomic approach suggests lipid homeostasis alterations in Ptchd1-/y 
mice but more work is needed to understand the dysfunctions at a sub-cellular level. As 
previously discussed, Ptchd1 shares an SSD with the cholesterol transporter NPC1. Thus, the 
first aim is to image cholesterol trafficking to ask whether Ptchd1 deficient cells have either 
an accumulation, downregulation or mislocalization of intracellular cholesterol. Filipin staining 
is a well described method used to visualize cholesterol (Gimpl, 2010). Filipin is a naturally 
fluorescent polyene that binds to free cholesterol. We aim to use Ptchd1-/y cerebellar cultured 
cells to image cholesterol with filipin staining. As cerebellar granule neurons have a very small 
condensed cytoplasm and dense dendritic arborization, they are not suitable for cholesterol 
visualization and quantification. To bypass that issue, we aim to use Ptchd1-/y cerebellar 
astrocytes. Our preliminary fluorescent in situ data (not shown) suggest that astrocytes 
express Ptchd1 mRNA; similarly, brain transcriptome database from Zhang et al. (2014) 
indicate that Ptchd1 is significantly expressed in human and mouse glial cells. In addition, 
astrocytes have a big and flat cytoplasm suitable for subcellular localization studies. Thus, we 
aim to image and quantify cholesterol with filipin staining in Ptchd1-/y and WT cultured 
astrocytes. 
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An alternative method to image cholesterol trafficking is the incorporation of 
fluorescent cholesterol analogs such as dehydroergosterol (DHE)-, cholestatrienol (CTL)- or 
bora-diaza-indacene (BODIPY)- cholesterol. Due to their lipophilic properties, these 
fluorescent analogs incorporate into cells and can be used for live cell imaging. Live imaging 
has the advantage of monitoring cholesterol trafficking dynamically overtime and not only at 
a given time point.  
 
Biosynthetic sterol trafficking can also be quantified in isolated sub-cellular 
compartments. Typically, radioactive cholesterol precursors (acetate or mevalonate) are 
incorporated in cells and the radiolabel incorporation into cholesterol is measured after sub-
cellular fractionation and lipid extraction (Gimpl, 2010). However, this method remains 
indirect and only provides enrichment of different sub-cellular membrane compartments.  
 
A recent method established by Tharkeshwar et al. (2017) used superparamagnetic 
iron oxide nanoparticles (SPIONs) to specifically isolate subcellular compartments and 
measure membrane lipid composition. In brief, SPIONs have an inorganic magnetic core and 
an organic/inorganic shell. When the shell coated with aminolipids, the SPIONs remain 
adhered to the plasma membrane, whereas when coated with dimercaptosuccinic acid, 
SPIONs are targeted to late endosomes and lysosomes. The different cellular compartments 
are then magnetically isolated, providing a highly specific segregation between plasma 
membrane and late endosomes/lysosomes. Following the isolation procedure, the different 
compartments can be used for lipidomic and proteomic profiling. This would be an attractive 
method to further characterize the lipid deficits observed in Ptchd1-/y mice. 
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5.1 Mice  
 
Ptchd1 mutant mice were generated in C57BL/6N background in collaboration with 
the Mouse Biology Project at the University of California Davis. Targeting vector 
PRPGS00100_C_H03 (KOMP) was electroporated into JM8.N4 ES cell and colonies selected. 
The targeting cassette is based on the knock-out first vector design, replacing exon 2 of the 
Ptchd1 gene. Mice with germline transmission were mated with ROSA26-Flpe females (Jax 
stock no: 003946), backcrossed over ten generations with C57BL/6N mice, to remove FRT-
flanked genetrap/LacZ sequences, yielding a conditional allele. Germline ablation of exon 2 
was created by crossing with CMV-cre mice (Jax stock no: 006054).  The “knock-out first” mice 
generated by the Mouse Biology Project were deposited at the MMRRC repository. 
Genotyping of the knock-out mice was done as follows: The Ptchd1-/y allele was detected by 
PCR using primers 5’-AACACCATGACTGAAGCAACTTGGG-3’(CSD-Ptchd1-F) with 5’-
AGTGCTGAGGAGTTAGCTATGCAGG-3’(CSD-Ptchd1-R). The Ptchd1WT allele was detected using 
5’-AACACCATGACTGAAGCAACTTGGG-3’(CSD-Ptchd1-F) with 5’-
TCCAGAACTGAGAAATCAGGTTCGC-3’(CSD-Ptchd1-ttR). Only male mice were used for all 
experiments. Procedures related to animal experimentation were reviewed and approved by 
the Kantonales Veterinäramt Basel-Stadt.  
 
5.2 In situ hybridization, PCR analysis 
 
In situ hybridizations with chromogenic detection were done using digoxigenin labelled 
cRNA probes and were performed as previously described (Schaeren-Wiemers and Gerfin-
Moser, 1993). The DNA fragment encoding the Ptchd1 probe contained SP6 and T7 promoters 
flanking the 5’- or 3’-end, respectively, Ptchd1: 
CCGCTCTGCTCTAGGATGCTGCGGCAGGTTCTGCACAGGGGCTTGAGGACGTGTTTCTCCCGGCTTG
GCCACTTCATTGCCAGTCACCCGGTCTTCTTTGCTTCGGCGCCGGTGCTCATCTCCATCCTGCTCGGCG
CCAGCTTCAGCCGCTACCAGGTCGAAGAGAGCGTGGAGCACCTGCTGGCGCCCCAGCACAGCCTAG
CCAAGATCGAGCGCAACCTAGTCAACAGCCTCTTCCCGGTCAACCGCTCCAAGCACCGGCTCTACTCG
GACCTGCAGACCCCTGGGCGCTACGGCCGGGTCATTGTCACCTCCTACCAGAAAGCCAACATGCTAG
ACCAACATCACACGGACCTGA 
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Templates for in vitro transcription using SP6-polymerase (anti-sense probe) or T7-
polymerase (sense probe) were amplified by PCR using ISP-SP6-5' (5’-
CTATCGATTTAGGTGACACTATAGAAG-3’) and ISP-T7-3' (5’-
GAATTGTAATACGACTCACTATAGGGA-3’) primers.  
 
Fluorescent in situ hybridization was performed following the RNAscope Multiplex 
Fluorescent Assay protocol (Wang et al., 2012). The assay was performed on 20µm snap frozen 
P21 brain cryostat sections. Sections were cut between Bregma -1.46 and -2.40 including the 
dorsal hippocampus.  Ptchd1 transcripts were detected with a commercial Ptchd1 probe (ACD, 
Cat No. 489651). A negative control probe (ACD, Cat No. 320871) was used to assess the 
specificity of hybridization signals observed. In situ images were acquired on a Widefield Axio 
Scan Z1 slide scanner. 
 
For qPCR analysis, brain tissues were dissected in ice cold PBS, microdissected 
hippocampal sub-regions were isolated according to the protocol of Hagihara (Hagihara et al., 
2009). Tissue was homogenized in Trizol (Tri Reagent, SIGMA), followed by addition of 
Chloroform. After homogenization, sample were centrifuged for 15min at 16’000xg. The 
supernatant was used for RNA purification with the RNAeasy mini plus kit (Qiagen) following 
manufacturer’s instructions. 1µg of total RNA was reverse transcribed using random hexamers 
and ImProm-II Reverse Transcriptase (Promega). Quantitative RT-PCR was performed on a 
StepOne plus qPCR system (Applied Biosystems): Gene expression assays were done with the 
Power SYBR Green Master Mix (Applied Biosystems) and the comparative CT method. cDNA 
levels were normalized to the house keeping gene Gapdh cDNA. Primer sequences used with 
Power SYBR Green PCR Mastermix were as follows:  
Ptchd1: 5’-CAAGATCGAGCGCAACCTAG-3’ and 5’-ATGTTGGCTTTCTGGTAGGAG-3’ 
Gapdh : 5’-CTCGTGTGGATTTGGAGAG-3’ and 5’-AGTTCTCGAACTTCCTCCT-3’ 
Hprt: 5’-GATGAACCAGGTATGACCTAGATTTG-3’ and 5’-ATGGCCTCCCATCTCCTTCAT -3’ 
TDO2: 5'-ATGAGTGGGTGCCCGTTTG-3’ and 5'-GGCTCTGTTTACACCAGTTTGAG-3’ 
DSP: 5'-GCTGAAGAACACTCTAGCCCA-3’ and 5'-ACTGCTGTTTCCTCTGAGACA-3’ 
Mrg1b: 5'-CTGGCGAGATCACGATGACG-3’ and 5'-AAGCTACGCTGTTGTCTAACC-3’ 
 
Primers used to confirm Ptchd1 exon 2 deletion were:  
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Forward primer in Exon1: 5’-CCAACATGCTAGACCAACATCACA-3’  
Reverse primer in Exon3: 5’-TTTATGGTTCCAGCCTTGTGTTCA-3’  
 
5.3 Antibodies, cDNA expression vectors, western blots 
 
Polyclonal anti-Ptchd1 antibodies were raised in guinea pigs using synthetic peptides 
derived from the following Ptchd1 sequences: DFQKTSRVSERYLVT and VDIDSTRVVDQITTV. 
Peptides were conjugated to keyhole limpet hemocyanin (Eurogentec, Belgium). Anti-sera and 
affinity purified antibodies were tested on Western blot applications; immunohistochemical 
applications were inconclusive. For Western Blots the following commercial antibodies were 
used: mouse anti-actin (JLA20-S, DSHB) 1:3000, mouse anti-GFP (abcam, ab38689) 1:500 
Mouse anti-PSD95(DLG4) (NeuroMab, 75-028) 1:3000, rabbit anti-VPS35 (Bethyl, A304-727A) 
1:200, mouse anti-vGlut1 (NeuroMab, 75-066) 1:3000. For immunohistochemistry assays the 
following antibodies were used: rat anti-BrdU (Abcam, ab6326) 1:50 and rabbit anti-Phospho 
Histone 3 (PH3) (Millipore, 06-570) 1:1000 
 
Immunoblotting was done with HRP-conjugated secondary antibodies (Jackson 
immunoresearch) and Pierce ECL Western blotting substrate. Signals were acquired using a 
digital imager (Bio-Rad, ChemiDoc MP Imaging System). The pEGFP-C1-Ptchd1 vector used for 
overexpression assays was created with the following cDNA: MG219209 from OriGene. 
 
5.4 BrdU incorporation assays and diolistic labeling.  
 
Postnatal day 4 (P4) Ptchd1-/y males and littermate wild-type controls were weighed, 
then injected intraperitoneally with 100mg/kg Bromodeoxyuridine (BrdU). After 30 minutes, 
mice were sacrificed, brains were transferred to fixative (4% paraformaldehyde, 30% Sucrose 
in PBS) and incubated overnight at 4°C. On the next day, brains were frozen at -80°C and 30µm 
cryosections were cut for immunohistochemistry. For the adult neurogenesis assay, P60 
Ptchd1-/y males and wild-type littermate controls were used and analyzed 4 days after 
injection of BrdU. Sections underwent an antigen retrieval step before the standard 
immunostaining protocol: in brief, sections were wash 3 times in PBS, put 0.1% TritonX-100 in 
PBS for 20min, transferred to 2M HCl for 20min at 37°C, neutralized with borate buffer (0.1M, 
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pH=8.5) 3 times for 10 min and washed in PBS 3 times for 10 min. Then a standard 
immunostaining protocol was applied for BrdU and PH3 detection. Quantitative assessment 
of BrdU-positive cells was performed as previously described (Han et al., 2008; Li et al., 2013). 
Briefly, confocal image stacks were acquired from consecutive sagittal sections of cerebellum 
lobule VI and dorsal dentate gyrus. An anatomically equivalent block of 300 - 400 µm thickness 
was analyzed for each animal (10-15 30µm anatomical sections per mouse, with each section 
imaged as a confocal image stack). For the adult neurogenesis experiment the neurogenic sub-
granular zone of the dentate gyrus was analyzed for BrdU- and PH3-positive cells. For the P4 
developmental hippocampus experiment the entire DG area was analyzed. 
 
The diolistic labeling (Gan et al., 2000) was performed according to a published 
protocol (Staffend and Meisel, 2011). Images were acquired on an inverted LSM700 confocal 
microscope (Zeiss) using 10x, 20× or 63x Apochromat objectives and controlled by Zen 2010 
software. For spine counting, confocal image stacks were acquired of granule cell dendritic 
segments in the distal molecular layer of the dorsal dentate gyrus. Spines were counted per 
30µm dendritic segment by evaluating the three-dimensional information of the image stacks. 
Headed and non-headed spines were distinguished manually. Images for display were 
assembled using Adobe Photoshop and Illustrator software. All quantitative assessments were 
performed by an investigator blinded to the genotype. 
 
5.5 Sonic hedgehog binding assay 
 
We modified a protocol from Cheng and Flanagan (Cheng and Flanagan, 2001). In brief, 
12 mm glass coverslips were coated with 100 µg/ml Poly-L-lysine (Sigma) for 2 h, and then 
washed twice with water. MEF or COS7 cells were plated on uncoated or PLL-coated 12 mm 
glass coverslips respectively, in 24-well plates. Cells were transfected with either pEGFP-C1-
Ptch1 + Casp9-DN-HA (HA-tagged dominant negative caspase 9, to prevent apoptosis) (Mille 
et al., 2009), pEGFP-C1-Ptchd1, or pEGFP-C1-NPC1, using Lipofectamine 3000 according to the 
manufacturer’s instructions. 48 h later, the media was removed and the cells washed twice 
with Binding Buffer A (BBA: DMEM + 10% FBS + 0.1% NaN2 + 50 mM HEPES). 500 nM Shh-Fc, 
diluted in BBA, was then added to the cells and incubated for 1 h at room temperature. Cells 
were then washed once in BBA, then three times in PBS (containing Ca2+ and Mg2+), followed 
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by fixation with 4% PFA for 10 minutes at room temperature. Shh-Fc was detected with 
standard immunostaining protocols using Cy3-conjugated donkey anti-human-Fc, diluted 
1:1000 in PBS with 1% normal donkey serum and 0.1% Triton X-100, for 1.5 h at room 
temperature. The coverslips were imaged on a Leica DM6B microscope with a Hammamatsu 
Orca Flash 4.0 camera, using Leica LASX software. Shh-Fc binding to Ptch-expressing cells 
results in a distinct cell surface staining pattern. The percentage of cells exhibiting binding was 
scored by an investigator blinded to the identity of the transfected cDNA. The assay was 
conducted three times, twice with COS7 cells and once with mouse embryonic fibroblast cells 
yielding similar results. Surface expression of overexpressed proteins was confirmed by 
surface biotinylation and revealed similar surface levels of Ptch and Ptchd1 proteins. 
 
5.6 Biochemical interaction assays 
 
cDNA encoding fusion peptide sequences used for pull-down analysis were inserted in 
frame in a pET9d-His6-GST vector. Plasmids were transformed in BL21 Rosetta E. coli. Bacteria 
were grown to reach OD=0.8. Expression was induced with 200µM IPTG for 2.5 hours at 25°C. 
Bacteria were pelleted at 5’000 x g at 4°C for 20 min, lysed and purified on Protino Ni-TED 
2000 columns (Machery-Nagel). Purified proteins were dialyzed overnight at 4°C against 
storage buffer (PBS, 2mM EDTA, 10% Glycerol, 0.1mM AEBSF, 0.1mM TCEP). For affinity 
purification of binding partners, Ptchd1 peptides were bound to Glutathione Sepharose 4 fast 
flow beads (GE Healthcare, #17-5132-01) following the manufacturer’s instructions. For the 
input fractions: adult male mouse brains (n=3) were lysed and homogenized in ~1.5ml/gr in 
an ice cold glass homogenizer and centrifuged at 800 x g at 4°C for 10min. The supernatant 
was transferred to a new tube and centrifuged at 16’000 x g at 4°C for 15min. The resulting 
supernatant was used as “Soluble fraction input”, the pellet, re-suspended in lysis buffer was 
used as “Membrane fraction Input”. GST beads were washed three times with PBS before 
adding the Input fractions. Beads were incubated with protein extracts for 2 hours at room 
temperature, then washed again three times with 0.1%TX-100 in PBS, followed by elution with 
2% sodium deoxycolate in 130ul. Eluted samples were trypsin digested and prepared for mass 
spectrometry following standard protocol. 
 
5.7 Mass spectrometry analysis and label-free quantification 
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Samples were subjected to LC–MS analysis in triplicates using a dual pressure LTQ-
Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) connected to an electrospray ion 
source (Thermo Fisher Scientific) as described (Glatter et al., 2012). Peptide separation was 
carried out on an EASY nLC-1000 system (Thermo Fisher Scientific) equipped with a RP-HPLC 
column (75 μm × 30 cm) packed in-house with C18 resin (ReproSil-Pur C18–AQ, 1.9 μm resin, 
Dr. Maisch GmbH). A linear gradient from 95% solvent A (0.15% formic acid, 2% acetonitrile) 
and 5% solvent B (98% acetonitrile, 0.15% formic acid) to 28% solvent B over 90 min at a flow 
rate of 0.2 μl/min was used. Data acquisition mode was set to obtain one high resolution MS 
scan in the FT part of the mass spectrometer at a resolution of 240,000 full widths at half-
maximum (at m/z 400) followed by 20 MS/MS scans in the linear ion trap of the most intense 
ions (TOP20) using rapid scan speed. Unassigned and singly charged ions were excluded from 
analysis and dynamic exclusion duration was set to 30 s. 
MS1-based label-free quantification of MS data was performed using Progenesis QI software 
(Nonlinear Dynamics (Waters), version 2.0). 
 
MS raw files were imported into Progenesis QI software and analyzed using the default 
parameter settings. MS/MS-data were exported from the software in “mgf” format and 
searched with a target/decoy strategy against a database containing forward and reverse 
sequences of the proteome from Mus musculus (UniProt, 33,984 entries) using MASCOT 
(version 2.4.1). Search criteria required full tryptic specificity allowing for three missed 
cleavages. Carbamidomethylation of cysteine was specified in Mascot as a fixed modification. 
Oxidation of methionine and acetyl of the N-terminus were specified in Mascot as variable 
modifications. Mass tolerance was set to 10 ppm for precursor ions and 0.6 Da for fragment 
ions. The peptide and protein false discovery rate (FDR) was set to 1%. Results from the 
database search were imported into Progenesis QI and the resulting peptide measurement 
list containing peak area values of identified peptides was exported. Processing and statistical 
evaluation of peptide and protein quantities between samples was performed using 
SafeQuant (Glatter et al., 2012). Normalized peptide and protein intensities from SafeQuant 
analysis were used to calculate intensity ratios, log2 ratios and q values between experimental 
conditions for identified proteins. 
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5.8 Synaptosome preparation 
 
Adult male mouse brain was homogenized with a glass homogenizer in 20µl/mg tissue 
0.32M Sucrose, 1mM NaHCO3, 1mM MgCl2, 0,5mM CaCl2 and complete EDTA-free protease 
inhibitor (Roche Applied Science). The homogenate was centrifuged at 1’400 x g for 10 min. 
The supernatant was further centrifuged at 16’000 x g for 20 min at 4°C resulting in the crude 
synaptosomal pellet and a cytosolic supernatant. The pellet was re-suspended in 1 mM 
NaHCO3, 0.32 M sucrose and loaded on top of a sucrose step gradient (1 M, 1.2 M sucrose) 
and centrifuged at 82’500 x g for 2 h. Synaptosomes were collected at the interface between 
the 1.0 M and 1.2 M sucrose layers. The synaptosome fraction was extracted for 15 min at 
4 °C in 25 mM Tris-HCl pH 8.1, 0.32 M sucrose, 1 % Triton X-100 and centrifuged at 32,800 x g 
for 30 min to yield a Triton X-100 soluble and insoluble (PSD) fraction. 
 
5.9 Mouse behavior analysis. 
 
Behavioral testing was done as previously described  (Leger et al., 2013; Nguyen et al., 
2016). We used wild-type littermate control and Ptchd1-/y male mice aged between 7 and 9 
weeks. Behavioral tests were done on three mouse cohorts (total n=10 Ptchd1-/y, n=8 wild-
type littermate). Mice were first tested in an open field arena (50x50×25 cm) and then the 
object recognition test was initiated on the following day in the same arena.  Before each 
behavioral test, mice were allowed to habituate to the behavioral room for at least 30 min. 
After each testing, the arena and objects were cleaned with 70% ethanol. Explorative behavior 
in the open field was recorded for 7 mins with a BASLER Ethovision Camera (Noldus). The 
distance traveled and mobility state were quantified using Ethovision 10 software (Noldus). 
The user-defined thresholds for definition of the high mobility state was set to 60% of changed 
pixel area. The open field test served as a habituation phase for the novel object recognition 
test.  For the novel object recognition test, recordings were acquired with a Canon camera 
(LEGRIA HFG10).  
 
Animals were allowed to explore two identical small Falcon tissue culture flasks (50 ml 
volume) filled with sand for 5 min. Then mice were returned to their home cage. After a 1 hr 
inter-trial interval, one flask was replaced with a tower of Lego bricks and duration of 
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interaction was assessed in a second 5 min trial. Exploration time for each object was 
measured manually by an investigator blinded to the genotype of the mouse. If a mouse 
exhibited less than 3 s exploring one object during the initial exposure, it was excluded from 
the analysis (this was the case for 2 KO animals). Object exploration was defined as the 
orientation of the mouse snout toward the object, sniffing or touching with the snout within 
2 cm distance. Leaning, climbing, looking over or biting the objects were not considered as 
exploration time. The position of the objects in the test was counterbalanced between the 
animals in a group. 
 
5.10 Electrophysiology 
 
Horizontal hippocampal slices (300 µm) were prepared from both hemispheres of age-
matched mice (P21-24) anesthetized with intraperitoneal injection of ketamine/xylazine 
(100mg/kg and 10mg/kg, respectively). Mice were transcardially perfused with an ice-cold 
oxygenated (95% O2/5% CO2) NMDG-based dissection buffer (Ting et al., 2014) (in mM): 93 
NMDG, 93 HCl, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 25 Glucose, 20 HEPES, 5 Na-ascorbate, 3 Na-
pyruvate, 2 Thiourea, 10 MgSO4, and 0.5 CaCl2, pH 7.4, 310 mOsm.  Slices were cut with a 
vibratome (VT1200S, Leica, Buffalo Grove, IL) in oxygenated NMDG-dissection buffer. Slices 
were transferred to NMDG-based oxygenated dissection buffer at 32°C for 15 min and then 
transferred to room temperature artificial cerebrospinal fluid (ACSF; in mM): 124 NaCl, 2.5 
KCl, 1.2 NaH2PO4, 2 CaCl2, 2 MgSO4, 24 NaHCO3, 5 HEPES, and 13 glucose, pH 7.4, 310 mOsm. 
Slices incubated at room temperature at least one hour to allow for recovery, then transferred 
to the recording chamber and perfused (1.5–2.0 ml/min) with oxygenated ACSF at room 
temperature.  
 
Somatic whole-cell recordings were made from granule cells in the dentate gyrus, 
which were voltage clamped with a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, 
CA) and identified using infrared-differential interference contrast video microscopy, digitized 
by Digidata 1440a (Molecular Devices). Patch pipettes (4–8 MΩ) were filled with voltage clamp 
(Vc) solution for paired-pulse facilitation, Excitation/Inhibition ratio, and sEPSC/sIPSC, 
experiments (in mM): Vc = 135 CsMeSO3, 10 HEPES, 8 NaCl, 0.3 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 
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5 QX-314 and 0.1 spermine, 295 mOsm. We measured excitatory postsynaptic currents by 
voltage-clamping granule cells to -70 mV, near the reversal potential for inhibition.  
 
Inhibitory postsynaptic currents were measured by voltage-clamping granule cells to 0 
mV, near the reversal potential for excitation. Data were filtered at 2 kHz, digitized at 10 kHz, 
and analyzed with Clampfit 10.6 (Molecular Devices). Perforant path (pp) afferents were 
stimulated with a small glass bipolar electrode (Master-9 and ISO-Flex Stimulator, A.M.P.I., 
Jerusalem, Israel). Short-term facilitation was induced with five stimuli of equal intensity 
presented at variable interstimulus intervals, ranging from 25 ms to 200 ms. Peak amplitudes 
measured from the responses from stimulations delivered at various frequencies were 
quantified and normalized to the first peak amplitude in a train. Responses from at least ten 
sweeps for each stimulation frequency were quantified to generate the facilitation ratios.  
 
AMPAR/NMDAR ratios were recorded in the presence of 10 µM Bicuculline (Tocris). 
The average of the maximal peak from ten evoked EPSCs voltage clamped at -70mV and the 
average of the maximal peak of ten evoked EPSCs voltage-clamped +40mV (50ms following 
the maximal peak recorded at -70mV) were used to quantify AMPAR/NMDAR ratios. 2.5 
minutes of recorded granule cell neurons voltage-clamped at -70mV for sEPSC and 0 mV for 
sIPSC were analyzed with Axograph X software (version 1.5.4) to determine the amplitude and 
frequency of sEPSCs and sIPSCs. The average of the maximal peak from ten evoked EPSCs 
voltage clamped at -70mV and the average of the maximal peak of ten evoked EPSCs voltage-
clamped at 0mV were used to quantify Excitation/Inhibition ratios.  
 
5.11 Lipid Extraction  
 
Similarly to (Guri et al., 2017), lipid extraction was performed using a modiﬁed MTBE 
protocol. Brieﬂy, cerebellar samples from  21 days old mice (n=4 WT; n=4 KO) were extracted 
and immediately snap-frozen in liquid nitrogen. Subsequently, tissues were pulverized into a 
ﬁne powder in an in-house-constructed metal mortar, pre-cooled on dry ice. Of that, 30-35 
mg ground liver tissue was weighed in a pre-chilled 2 mL Eppendorf Safe-Lock tube and 
resuspended in 100 mlH2O and transferred into a 2 mL Eppendorf tube. Then, 360 ml 
methanol was added and vortexed. A mixture of lipid standards (see Key Resources Table) 
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plus 50 ml 1.4 mm Zirconium glass beads (Bertin Technologies, France) were added and the 
pulverized tissue was homogenized using a Cryolysis System (Bertin Technologies, France) 
(program: 6200-3x45-045) cooled to 4°C. MTBE (1.2 mL) was then added and the sample was 
incubated for one hr at room temperature with shaking (750 rpm). Phase separation was 
induced by adding 200 mlH2O. After 10 min of incubation at RT, the sample was centrifuged 
at 1000 x g for 10 min (RT). The upper (organic) phase was transferred in a 13 mm screw cap 
glass tube and the lower phase was extracted with 400 ml artiﬁcial upper phase 
(MTBE/methanol/water (10:3:1.5, v/v)). The two upper phases were combined and the total 
lipid extract was divided in 3 equal aliquots (one for phospholipids (TL), one for sterols (S) in 2 
mL amber vials and one for sphingolipid 
(SL) detection in a 13 mm glass tube) and dried in a Centrivap at 50°C or under a nitrogen ﬂow. 
The TL and S aliquots were ready to be analyzed by mass spectrometry and were kept at -
80°C. The SL aliquot was deacylated to eliminate phospholipids by methylamine treatment 
(Clarke method). 0.5 mL monomethylamine reagent (MeOH/H2O/n-butanol/Methylamine 
solution (4:3:1:5 v/v) was added to the dried lipid, followed by sonication (5 min). Samples 
were then mixed and incubated for one hr at 53°C and dried (as above). The 
monomethylamine treated lipids were desalted by n-butanol extraction. 300 mlH2O saturated 
n-butanol was added to the dried lipids. The sample was vortexed, sonicated for 5 min and 
150 ml MS grade water was added. The mixture was vortexed thoroughly and centrifuged at 
3200 x g for 10 min. The upper phase was transferred in a 2 mL amber vial. The lower phase 
was extracted twice more with 300 mlH2O saturated n-butanol and the upper phases were 
combined and dried (as above). 
 
5.12 Lipidomic analysis and quantification 
 
Similarly to (Guri et al., 2017),  phospholipid and Sphingolipid Detection were done on a Triple 
Quadrupole TSQ Vantage (ThermoFischer Scientiﬁc). LC-MS or HPLC grade solvents were used 
and the samples were pipetted in a 96 well plate (ﬁnal volume = 100 ml). Positive mode 
solvent: Chloroform/Methanol/Water (2:7:1 v/v) + 5mM Ammonium Acetate. Negative mode 
solvent: Chloroform/Methanol (1:2 v/v) + 5mM Ammonium Acetate. The TL and SL aliquots 
were resuspended in 250 ml Chloroform/methanol (1:1 v/v) and sonicated for 5 min. The TL 
were diluted 1:50 in negative and positive mode solvents and the SL were diluted 1:10 in 
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positive mode solvent and infused onto the mass spectrometer. Tandem mass spectrometry 
for the identiﬁcation and quantiﬁcation of phospho- and sphingo-lipid molecular species was 
performed using multiple reaction monitoring (MRM) with a TSQ Vantage Triple Stage 
Quadrupole Mass Spectrometer (Thermo Fisher Scientiﬁc) equipped with a robotic nanoﬂow 
ion source, Nanomate HD (Advion Biosciences, Ithaca, NY). The collision energy was optimized 
for each lipid class. The detection conditions for each lipid class are listed below. Ceramide 
species were also quantiﬁed with a loss of water in the ﬁrst quadrupole. Each biological 
replicate was read in 2 technical replicates (TR). Each TR comprised 3 measurements for each 
transition. Lipid concentrations were calculated relative to the relevant internal standards and 
then normalized to the total phosphate content of each total lipid extract, as described in 
(Ding et al., 2013 ). Data was then normalized to age-matched control 
 
5.13 Statistical analysis and experimental design 
 
Statistical analysis was done with Prism software (GraphPad software). Images from 
immunohistochemical and dye labeling experiments were analyzed in Fiji (Image J) with 
manual cell or spine counting. Sample sizes are chosen based on previous examples from the 
literature, and variation observed in the experiment. Exclusion criteria were animal weight 
which differed from the population mean by at least 20% or severe behavioral alterations 
observed in single animals before the experiment. No animals were excluded in the present 
study. Blinding was applied as stated for each experimental procedure below. 
 
The qRT-PCR analysis was performed with n=3 mouse brain tissues for each time point 
and brain area. Data was analyzed with multiple comparison one-way ANOVA test. P values 
(Tukey’s multiple comparison test) are shown in Figure 1E. 
 
The FISH in situ quantification was done with N=3 WT mice; n=22 hippocampi (11 
coronal sections with 6 to 8 hippocampi per animal). 
 
The developmental BrdU analysis was performed with N=5 mice per genotype (for EGL 
, n= 65 Ptchd1-/y, 61 WT sections; for the hippocampal study  n= 61 Ptchd1-/y, 61 WT sections). 
Cells positive for either BrdU or PH3 were normalized to the EGL area. The P4 hippocampal 
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analysis was normalized to the dentate gyrus area. Cell densities assessed per section were 
averaged per animal and genotype differences analyzed with an unpaired t-test using the 
number of animals as “N”. P-values are shown in Figure 3 B and D. 
 
The adult neurogenesis analysis was done with N=5 mice per genotype (n=78 Ptchd1-
/y sections; n=80 WT sections). All BrdU/PH3 scoring was done blinded to genotype. Cells in 
the sub-granular zone positive for either BrdU or PH3 were normalized to the length of the 
sub-granular zone. Sections were averaged per animal and genotype differences were 
analyzed with an unpaired t-test, p-values are shown in Figure 4B. Shh-Fc binding 
quantification was analyzed on N≥103 COS7 cells and N≥40 MEF cells.   
 
 In the diolistic experiments, image acquisition and spine counting analysis was done 
by an investigator blinded to genotype, for P21 N=4 Ptchd1-/y and N=4 WT; n=44 anatomical 
sections per genotype, for P60 N=5 Ptchd1-/y and N=4 WT; Ptchd1-/y n=49, WT n=42 sections. 
Spine densities per dendritic segment were averaged per animal and genotype differences 
were analyzed with an Unpaired t-test, p-values are shown on Figure 6B. The open field 
behavioral data was obtained with automated video tracking software Ethovision 10. The data 
was analyzed with an unpaired t-test; p-values are shown in Figure 7. 
 
All behavioral tests were analyzed by an investigator blinded to the genotype. For the 
novel object recognition test, the initial exploration time was analyzed with an unpaired t-
test. Interaction times with objects A and B were analyzed with a repeated measure two-way 
ANOVA test. Discrimination ratios were analyzed with an unpaired t-test. The habituation time 
to object A was analyzed with a repeated measure two-way ANOVA test (Figure 7G).  
 
The electrophysiological characterization was performed with n≥10 cells and N=3 mice 
per genotype by an investigator blinded to genotype. An unpaired t test was used to assess 
significance in excitation/inhibition ratios, sEPSC, and sIPSC data. A two-way repeated 
measures ANOVA with a Sidak’s multiple comparisons test was used to assess significance in 
short-term plasticity experiments.  
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6.1 Challenges to localize the Ptchd1 protein 
 
As commercial antibodies against Ptchd1 are not available, we started the project with 
in vitro Ptchd1 over-expression assays. We used plasmids containing the Ptchd1 sequence 
fused with either an HA-tag or the enhanced green fluorescent protein (EGFP). In COS cells 
overexpressing Ptchd1-EGFP, Ptchd1 co-localizes with the ER marker calnexin (expression 
pattern is similar with the HA-tag and with HEK cells, data not shown). Over-expressed 
proteins, when not properly processed by the cell, often tend to aggregate in the ER, so it is 
unclear whether this pattern reflects a potential localization of Ptchd1 in the ER or if the 
protein is simply stuck up in the ER. Also, depending on plasmid amounts, low Ptchd1 
expression was also observed at the plasma membrane. In addition, over-expression assays in 
neuronal cultures were inconclusive (cells died after transfection). 
 
 
 
Figure 15. Ptchd1-EGFP over-expression in COS cells. Fluorescent imaging of COS cells 
overexpressing Ptchd1-EGFP (left). Transfected cells were immunostained with the ER marker, calnexin 
(middle). Merged signals show important co-localization of Ptchd1-EGFP with calnexin (Yang et al.). 
 
 
In parallel, we generated several “home-made” anti-Ptchd1 antibodies raised against 
different parts of the protein. One antibody successfully recognized the protein in western 
blot assays and was used to validate the Ptchd1-/y mouse line (Figure 8). However, despite 
considerable effort spent generating different antibodies, none of the sera (even when 
purified) were suitable for immunohistochemical assays. 
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To circumvent the problem, a knock-in mouse line expressing a fluorescently labeled 
Ptchd1 is being generated. The fluorescent tag used is a modified GFP protein with more 
stable and stronger fluorescence called NeonGreen (NG). Similarly to Feng et al. (2017) the 
NG protein is split in two parts: the 11th beta-strand of NG is fused to Ptchd1 for endogenous 
expression and the other part of the protein (NG 1-10th) can later be transfected, 
electroporated or virally infected exogenously. The NG protein become fluorescent only when 
the two parts expressed in the cell bind covalently and irreversibly (Figure 16A). Thereby, the 
exogenous addition of NG 1-10th allows to sparsely label and live-track Ptchd1 in a subset of 
cells (with the use a specific promoters) and in a temporally controlled manner. 
 
We used the Crispr-Cas9 genetic engineering tool to knock-in the NG 11th strand to the 
N-terminal sequence of Ptchd1. In brief, an exogenous single stranded DNA sequence 
encoding for NG-11th along with a guide RNA (gRNA) and the Cas9 enzyme are injected in 
mouse oocytes; the gRNA serves as a guide for the Cas9 enzyme to cut the DNA upstream 
from the desired PAM motif, the homology arms of the donor DNA can then anneal to the 3’ 
cut DNA strand and thereby insert the donor DNA sequence in the mouse genome (Figure 
16B). Injected oocytes are then transferred in pseudo-pregnant mice and the resulting litters 
are genotyped and sequenced for correct DNA insertion.  
 
Several experiments are ongoing or planned to assess whether or not this tool 
efficiently labels Ptchd1. Ptchd1-NG-11th mice can be used for several localization assays. For 
instance, cerebellar Ptchd1-NG-11th neuronal cultures infected with a virus carrying NG 1-10th 
can be used for live imaging studies. Alternatively, a promoter driven virus carrying the NG 1-
10th can be directly injected in Ptchd1-NG-11th mice brain allowing sparse labeling of Ptchd1 
in a cell type specific manner.  
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A 
 
B 
Figure 16. Ptchd1-NeonGreen mouse line engineering. A, The 11th beta strand of the 
NeonGreen protein (NG-11) is fused to the N-term of Ptchd1. When the NG 1-10 part of the 
protein is added to a cell expressing Ptchd1-NG-11, the two parts covalently bind and restore 
fluorescence. B, Genetic engineering of the NG-11 knock-in: the guide RNA (blue) guides the 
Cas9 enzyme (grey) to make a double stranded DNA cut (red) upstream of the selected PAM 
motif. The cut 3’ strand will anneal to the homology arm of the single stranded donor DNA 
encoding for the NG-11 part. DNA repair mechanisms will insert the knock-in sequence on the 
complementary 5’ strand. 
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6.2 Index of Figures  
 
1. Introduction: 
 
 Figure 1. Heterogeneity of ASD comorbidities 
 
 Figure 2. Genetic architecture of ASD (de la Torre-Ubieta et al., 2016) 
 
Figure 3. Prevalence of core and associated ASD symptoms in PTCHD1 muted individuals 
 
 Figure 4. Schematic representation of the Ptchd1 protein 
 
 Figure 5. Gene tree of PTCHD1 
 
 Figure 6. Phylogenetic tree of sterol sensing domains  
 
2. Results: 
 
  Figure 7. Ptchd1 mRNA distribution in the mouse brain 
 
  Figure 8. Ptchd1 knock-out mouse generation and validation 
 
 Figure 9. Proliferation of neuronal precursors in developing Ptchd1-/y mice 
 
Figure 10. Adult neurogenesis in Ptchd1-/y mice and Shh binding to Ptchd1 
 
Figure 11. Ptchd1 cytoplasmic tail interacts with scaffolding proteins and retromer complex 
 
  Figure 12. Morphology and physiology of dentate gyrus granule cells in Ptchd1-/y mice 
 
  Figure 13. Ptchd1-/y  mouse behavioral analysis 
 
 Figure 14. Brain lipid changes in Ptchd1-/y mice 
 
6. Appendix: 
 
 Figure 15. Ptchd1-EGFP over-expression in COS cells 
 
  Figure 16. Ptchd1-NeonGreen mouse line engineering 
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6.3 Index of Abbreviations  
 
PTCHD1 Human Patched domain containing protein 1 (PTCHD1=human gene; 
Ptchd1=mouse gene, Ptchd1=mouse protein) 
ASD  Autism spectrum disorders 
ID  Intellectual disability 
Shh  Sonic hedgehog 
Ptch  Patched 
NPC1  Niemann-pick C-1 type 
DSM Diagnostic and statistical manual of mental disorders 
ICD World Health Organization’s International Statistical Classification of Diseases 
and Related Health Problems 
PDD Pervasive developmental disorders 
E/I ratio Excitatory over inhibitory ratio 
CNV Copy number variant 
SNP Single nucleotide polymorphism 
iPSCs Human induced pluripotent stem cells 
XLID X-chromosome linked intellectual disability 
SSD Sterol sensing domain 
Smo Smoothend 
EGFP Enhanced green fluorescent protein 
Pn Postnatal day n 
PH3 Phospho-histone 3 
Ptchd1-/y Ptchd1 male hemizygous knock-out  
KO Knock-out 
WT  Wild-type 
EGL External granule cell layer of the cerebellum 
MEF Mouse embryonic fibroblast 
ECD Extracellular domain/sequence 
GST Glutathione-S-transferase 
PSD Post-synaptic density 
EPSC Excitatory post-synaptic current 
   Appendix 
 101 
IPSC Inhibitory post-synaptic current 
sE/IPSCs Spontaneous excitatory or inhibitory post-synaptic current 
AMPAR Amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor 
NMDA  N-Methyl-D-aspartic acid receptor 
GPL  Glycerophospholipid 
PS  Glycerophospho-serine 
PE  Glycerophospho-ethanolamine 
PC  Glycerophospho-choline 
CM  Ceramide 
SM  Sphingomyelin 
TGN  Trans golgi network    
SPION  Superparamagnetic iron oxide nanoparticle
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